THE FOUNDATION FOR AIDS RESEARCH: Form 990, tax year 2024
View the entire original 990 at ProPublica ↗
- Organization
- THE FOUNDATION FOR AIDS RESEARCH (EIN 13-3163817)
- Tax period
- 2024-10-01 to 2025-09-30
- Filed
- 2026-07-21
- IRS object ID
- 202632029349300118
- Schema version
- 2024v5.5
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2026-07-21T08:25:12-05:00 | ReturnTs |
| Tax Period End | 2025-09-30 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 331374517 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | PKF O'CONNOR DAVIES ADVISORY LLC | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 500 MAMARONECK AVENUE SUITE 301 | AddressLine1Txt |
| City | HARRISON | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 105281633 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2024-10-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 133163817 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | THE FOUNDATION FOR AIDS RESEARCH | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | FOUN | BusinessNameControlTxt |
| Phone | 2128061600 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 120 WALL STREET 13TH FLOOR | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 100053908 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | SHAWN DAVIDSON | PersonNm |
| Person Title | CFO & COO | PersonTitleTxt |
| Phone | 2128061600 | PhoneNum |
| Signature | 2026-07-21 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IRS Responsible Prty Info Curr | Yes (1) | IRSResponsiblePrtyInfoCurrInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | MELISSA MODELSON | PreparerPersonNm |
| PTIN | P01603524 | PTIN |
| Phone | 9143818900 | PhoneNum |
| Preparation | 2026-07-15 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2024 | TaxYr |
| Build TS | 2025-03-06 01:10:19Z | BuildTS |
Form 990 IRS990
Doing Business As Name DoingBusinessAsName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | AIDS RESEARCH FOUNDATION AMFAR | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | KYLE CLIFFORD | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 120 WALL STREET 13TH FLOOR | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 100053908 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $57,092,341 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.AMFAR.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1983 | FormationYr |
| Legal Domicile State | NY | LegalDomicileStateCd |
| Activity Or Mission | AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. (SEE SCHEDULE O) | ActivityOrMissionDesc |
| Voting Members Governing Body | 14 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 14 | VotingMembersIndependentCnt |
| Total Employee | 71 | TotalEmployeeCnt |
| Total Volunteers | 14 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $39,707,167 | PYContributionsGrantsAmt |
| CY Contributions Grants | $48,171,885 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $0 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | $628,771 | PYInvestmentIncomeAmt |
| CY Investment Income | $1,647,098 | CYInvestmentIncomeAmt |
| PY Other Revenue | -$15,490,142 | PYOtherRevenueAmt |
| CY Other Revenue | -$15,035,039 | CYOtherRevenueAmt |
| PY Total Revenue | $24,845,796 | PYTotalRevenueAmt |
| CY Total Revenue | $34,783,944 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $4,204,529 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $6,385,611 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $11,595,593 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $12,071,981 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $546,678 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $437,122 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $6,300,485 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $13,218,711 | PYOtherExpensesAmt |
| CY Other Expenses | $14,446,835 | CYOtherExpensesAmt |
| PY Total Expenses | $29,565,511 | PYTotalExpensesAmt |
| CY Total Expenses | $33,341,549 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$4,719,715 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $1,442,395 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $53,354,032 | TotalAssetsBOYAmt |
| Total Assets EOY | $57,990,840 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $19,540,426 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $20,919,426 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $33,813,606 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $37,071,414 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | SEE SCHEDULE O | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $12,787,908 | ExpenseAmt |
| Grant | $3,706,225 | GrantAmt |
| Revenue | $6,132 | RevenueAmt |
| Desc | AS A LEADING NONPROFIT, AMFAR ADVANCES SCIENTIFIC DISCOVERY TO IMPROVE GLOBAL HEALTH, WITH A PRIMARY AND ENDURING COMMITMENT TO ENDING THE HIV/AIDS EPIDEMIC. SERVING AS A CATALYST FOR BREAKTHROUGH SCIENCE, AMFAR SUPPORTS INNOVATIVE RESEARCH IN AREAS WHERE VIRUSES AND THE IMMUNE SYSTEM PLAY A DEFINING ROLE, INCLUDING CANCER, NEUROLOGICAL CONDITIONS, AGING, AUTOIMMUNE DISORDERS, AND OTHER VIRAL DISEASES. FOR FURTHER DETAILS, SEE SCHEULE O. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $6,141,063 | ExpenseAmt |
| Grant | $2,649,385 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | TREAT ASIATHE ASIA-PACIFIC REGION IS HOME TO NEARLY 7 MILLION PEOPLE LIVING WITH HIV, THE WORLD'S LARGEST EPIDEMIC AFTER THAT IN EASTERN AND SOUTHERN AFRICA, WITH 23% OF ALL NEW INFECTIONS GLOBALLY. TREATMENT COVERAGE VARIES SIGNIFICANTLY ACROSS THE REGION, WHERE PEOPLE LIVING WITH AND AT RISK FOR HIV ARE ALSO CHALLENGED BY CO-INFECTIONS SUCH AS HEPATITIS, TUBERCULOSIS, AND MENTAL HEALTH ISSUES. WITH ITS NETWORK OF 21 ADULT AND 18 PEDIATRIC SITES IN 12 COUNTRIES ACROSS THE REGION, AMFAR'S TREAT ASIA PROGRAM BRINGS RESEARCHERS, HEALTH PROFESSIONALS, AND ADVOCATES TOGETHER TO IMPROVE STANDARDS OF CARE, EXPAND ACCESS TO TREATMENT AND PREVENTION, AND SUPPORT COMMUNITY-LED MONITORING OF HEALTH NEEDS ACROSS THE REGION. CHAMPIONING DATABASE-DRIVEN RESEARCHTREAT ASIA MANAGES THE ASIA-PACIFIC SECTION OF THE INTERNATIONAL EPIDEMIOLOGY DATABASES TO EVALUATE AIDS (IEDEA), A GLOBAL COLLABORATION ESTABLISHED BY THE U.S. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES. IEDEA IS CENTRAL TO THE INTERNATIONAL RESEARCH IN WHICH TREAT ASIA PARTICIPATES, RANGING FROM STUDIES ON TREATMENT OUTCOMES, CANCER SCREENING, AND CLINICAL OUTCOMES OF PULMONARY TB, TO MENTAL HEALTH CHALLENGES FACED BY ADOLESCENTS LIVING WITH HIV. THE INFORMATION GATHERED FROM TREAT ASIA'S OBSERVATIONAL RESEARCH DATABASES CONTINUES TO INFORM THE DEVELOPMENT OF MORE EFFECTIVE RESEARCH AND TREATMENT PROGRAMS AND HELP DEFINE TREATMENT STANDARDS SPECIFIC TO HIV/AIDS IN ASIA ALONG THE CONTINUUM OF CARE. THESE DATA ALSO INFORM STUDIES ON LYMPHOMA, HEPATITIS, SUBSTANCE USE, AND ALZHEIMER'S DISEASE, AMONG OTHER CONDITIONS. OTHER MAJOR DATABASE AND COHORT STUDIES ARE FOCUSING ON HIV TREATMENT FAILURE; MANAGEMENT AND OUTCOMES OF HIV AND TB; AND MENTAL HEALTH SCREENING AND LINKAGE TO CARE STRATEGIES.SUPPORTING ADOLESCENT HEALTH RESEARCHFOR ADOLESCENTS ACROSS SOUTHEAST ASIA, WHO REPRESENT ABOUT 30% OF THE GLOBAL ADOLESCENT POPULATION, THE CHALLENGE TO STAY HEALTHY IS COMPOUNDED BY HEALTH SYSTEMS THAT SOMETIMES LACK THE CAPACITY TO ADDRESS THEIR NEEDS.IN RESPONSE TO THESE GAPS, TREAT ASIA, IN COLLABORATION WITH LONGSTANDING PARTNER CHULALONGKORN UNIVERSITY'S SCHOOL OF GLOBAL HEALTH IN BANGKOK, ORGANIZED AN ADOLESCENT HEALTH AND RESEARCH MEETING, A TRAINING WORKSHOP DESIGNED TO STRENGTHEN ADOLESCENT HEALTH SERVICES AND RESEARCH CAPACITY ACROSS SOUTHEAST ASIA, IN SEPTEMBER 2025.TREAT ASIA IS A LEADER IN RESEARCH FOCUSED ON YOUNGER PEOPLE LIVING WITH HIV, SOME OF WHOM ACQUIRED HIV PERINATALLY. STUDIES FOCUSED ON ADOLESCENTS LIVING WITH AND AT RISK FOR HIV ADDRESS MENTAL HEALTH COLLABORATIVE CARE, CANNABIS USE, HUMAN PAPILLOMAVIRUS AND CANCER RISK, AND THE ASSOCIATIONS BETWEEN RISK-TAKING BEHAVIOR AND BRAIN HEALTH. THREE MULTI-YEAR STUDIES ARE DESCRIBED BELOW.THAI-PAPAYA (THAI PROGRAM TO ACTIVELY FOLLOW PERINATAL ADOLESCENTS AND YOUNG ADULTS LIVING WITH HIV): IMPLEMENTED IN FIVE SITES IN THAILAND, THIS STUDY EXAMINES LONG-TERM HIV TREATMENT OUTCOMES OF ADOLESCENTS AND YOUNG ADULTS LIVING WITH HIV, INCLUDING RETENTION IN CARE, MORTALITY, HEALTH-RELATED QUALITY OF LIFE, AND SEXUAL AND REPRODUCTIVE HEALTH, AMONG OTHER ISSUES. SUB-STUDIES ON CARDIOVASCULAR DISEASE, STIGMA AROUND HEALTHCARE TRANSITIONS, AND BEST PRACTICES FOR HELPING YOUNGER PEOPLE TRANSITION INTO ADULT CARE ARE ALSO BEING CONDUCTED.SUICIDAL BEHAVIOR AMONG THAI ADOLESCENTS LIVING WITH HIV (S-BETAH): THIS PROSPECTIVE COHORT STUDY AIMS TO DETERMINE THE PREVALENCE OF MENTAL HEALTH DISORDERS AND SUICIDAL BEHAVIOR FOLLOWING POSITIVE SCREENING AND LINKAGE TO MENTAL HEALTH SERVICES. A FOLLOW-UP PHASE IS ASSESSING THE PREVALENCE AND INCIDENCE OF SUICIDALITY AMONG THIS POPULATION COMPARED WITH THEIR HIV-NEGATIVE AGE- AND SEX-MATCHED COUNTERPARTS. ADOLESCENT AND YOUNG ADULT NETWORK OF IEDEA (AYANI): FOCUSING ON ADOLESCENTS AGED 1524 YEARS OLD, THIS GLOBAL STUDY ASSESSES CARE TRANSITIONS, CO-MORBIDITIES, MENTAL HEALTH CHALLENGES, AND FACTORS IMPACTING TREATMENT ADHERENCE, VIRAL SUPPRESSION, CARE ENGAGEMENT, AND MORTALITY. TEN MULTIREGIONAL AYANI RESEARCH CONCEPTS ARE IN DIFFERENT STAGES OF COMPLETION.HIV, HPV, AND CERVICAL CANCER: A DEADLY NEXUSREGULAR CERVICAL CANCER SCREENINGSPAP SMEARS AND TESTING FOR HUMAN PAPILLOMAVIRUS (HPV), THE PRIMARY CAUSE OF CERVICAL CANCERHELP DETECT CANCEROUS AND PRECANCEROUS CELLS EARLY, WHEN THEY ARE MOST TREATABLE. LOW UPTAKE OF CERVICAL HEALTH SCREENINGS, COMBINED WITH THE FACT THAT WOMEN LIVING WITH HIV ARE SUSCEPTIBLE TO CHRONIC, PERSISTENT HIGH-RISK HPV INFECTION (STRAINS MORE PRONE TO LEAD TO CANCER) AND ARE SIX TIMES MORE LIKELY TO DEVELOP CERVICAL CANCER THAN WOMEN WITHOUT HIV, PROMPTED TREAT ASIA NETWORK INVESTIGATOR DR. AGUS SOMIA, OF PROF. DR. NGOERAH HOSPITAL IN BALI, INDONESIA, TO STUDY THE ISSUE IN MORE DEPTH.THE STUDY COLLECTED DATA VIA INTERVIEWS AND CLINICAL EXAMS AT HIV OUTPATIENT CLINICS TO DETERMINE THE PREVALENCE AND RISK FACTORS OF HIGH-RISK HPV AND CERVICAL DYSPLASIA IN WOMEN LIVING WITH HIV. BASED ON ITS FINDINGS, THE STUDY RECOMMENDS INCREASING HPV VACCINATION AND CERVICAL CANCER SCREENING, PARTICULARLY FOR YOUNGER WOMEN, AND SCREENING ALL WOMEN LIVING WITH HIV IN INDONESIA IN ORDER TO IMPROVE HEALTH OUTCOMES.UNDERSTANDING ALZHEIMER'S AND HIV IN ASIAALZHEIMER'S DISEASEA DISORDER INVOLVING PROGRESSIVE DEGENERATION OF THE BRAIN AFFECTING COGNITION (MEMORY, THINKING, BEHAVIOR)IS THE MOST COMMON FORM OF DEMENTIA AMONG THE GENERAL POPULATION, ACCOUNTING FOR 60% TO 80% OF CASES. THE RISK OF ALZHEIMER'S INCREASES EXPONENTIALLY WITH AGE, AND THAT RISK INCREASES IN PEOPLE LIVING WITH HIV, FOR WHOM 30% TO 50% HAVE SOME FORM OF COGNITIVE IMPAIRMENT. ACCURATE DIAGNOSIS OF ALZHEIMER'S IS CRUCIAL SO THAT PHYSICIANS CAN WORK WITH PATIENTS TO MANAGE SYMPTOMS, EXPLORE TREATMENT OPTIONS, AND IMPROVE QUALITY OF LIFE.THANKS TO AN AMFAR-SUPPORTED STUDY, LED BY DR. AKARIN HIRANSUTHIKUL, OF CHULALONGKORN UNIVERSITY IN BANGKOK, THAILAND, RESEARCHERS HAVE SHOWN THAT A NEW METHOD OF DIAGNOSING ALZHEIMER'SA BLOOD-BASED BIOMARKERCOULD BE USEFUL IN PREDICTING COGNITIVE DECLINE IN PEOPLE LIVING WITH HIV. PARTICIPANTS WERE ENROLLED FROM COHORTS IN BANGKOK, THAILAND, AND KUALA LUMPUR, MALAYSIA.FOSTERING MENTAL HEALTH RESEARCHTHE OBJECTIVE OF TREAT ASIA'S CHIMERA PROGRAM (CAPACITY DEVELOPMENT FOR HIV AND MENTAL HEALTH RESEARCH IN ASIA) IS TO ADDRESS THE DUAL AND INTERLINKED BURDENS OF HIV AND MENTAL HEALTH. CO-LED BY PRINCIPAL INVESTIGATORS DR. ANNETTE SOHN AND DR. MILTON WAINBERG OF COLUMBIA UNIVERSITY, THE PROGRAM AIMS TO BUILD GROUPS OF INVESTIGATORS WITHIN THE ASIA-PACIFIC WITH THE CAPACITY TO LEAD REGIONAL HIV-MENTAL HEALTH-IMPLEMENTATION SCIENCE RESEARCH THAT INFORMS PUBLIC HEALTH POLICY AND IMPROVES CLINICAL CARE.CHIMERA BRINGS TOGETHER STELLAR TRAINING FACULTY FROM ACADEMIC CENTERS AND PUBLIC HEALTH ORGANIZATIONS WITHIN THE REGION AND ACROSS THE WORLD, AND BUILDS ON EXISTING NIH-FUNDED MENTAL HEALTH RESEARCH BEING CONDUCTED THROUGH IEDEA ASIA-PACIFIC. THE PROGRAM WAS RENEWED BY THE NIH FOR ANOTHER FIVE YEARS IN SEPTEMBER 2025. A NEW CLASS OF SIX FELLOWS INCLUDES DR. NAROM PRAK (CAMBODIA), DR. LIM QUAN HZIUNG AND PREETHI RAGHAVAN (MALAYSIA), DR. RUTH ANNE B. HECHANOVA-CRUZ (PHILIPPINES), AND DRS. NADVADEE AUNGKAWATTANAPONG AND MAYTEEWAT CHIDDAYCHA (THAILAND). THROUGHOUT THE YEAR, THE FELLOWS MADE STRIDES IN THEIR TRAINING ACTIVITIES AND ARE PREPARING TO CONDUCT PILOT RESEARCH STUDIES AS PART OF THE CURRICULUM. SHARING RESEARCH FINDINGSTREAT ASIA INVESTIGATORS PUBLISHED 28 SCIENTIFIC PAPERS IN PEER-REVIEWED MEDICAL JOURNALS IN 2025. THESE FINDINGS ARE SHARED IN PART THROUGH THE PARTICIPATION OF TREAT ASIA IN REGIONAL AND INTERNATIONAL CONFERENCES. TREAT ASIA HAD A STRONG PRESENCE AT THE 2025 INTERNATIONAL AIDS SOCIETY CONFERENCE ON HIV SCIENCE IN KIGALI, RWANDA, IN JULY 2025, WITH TREAT ASIA STAFF AND PARTNER INVESTIGATORS DELIVERING 12 POSTERS AND PRESENTATIONS ON TOPICS RANGING FROM PREP AND MEDICATION ADHERENCE TO KIDNEY DYSFUNCTION AND MENTAL HEALTH SERVICE INTEGRATION. ABSTRACTS WERE ALSO PRESENTED AT THE INTERNATIONAL WORKSHOP ON HIV, SRHR, & ADOLESCENCE (OCTOBER 2024), THE CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (MARCH 2025), AND THE ASIA-PACIFIC AIDS AND CO-INFECTIONS CONFERENCE (JUNE 2025), AMONG OTHERS. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $3,219,765 | ExpenseAmt |
| Grant | $0 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | PUBLIC INFORMATIONAMFAR TRANSLATES AND DISSEMINATES INFORMATION ON IMPORTANT HIV-RELATED RESEARCH, TREATMENT, PREVENTION, AND POLICY ISSUES FOR DIVERSE AUDIENCES TO INCREASE AWARENESS AND KNOWLEDGE OF THE PANDEMIC. AMFAR PUBLISHES A WIDE RANGE OF EDUCATIONAL MATERIALS, MAINTAINS AN INFORMATIVE WEBSITE, WORKS CLOSELY WITH THE MEDIA TO RAISE THE PROFILE OF HIV/AIDS, BOTH DOMESTICALLY AND INTERNATIONALLY, AND TO HELP ENSURE THE ACCURACY OF HIV-RELATED PRESS COVERAGE, AND ENGAGES RESPECTED PUBLIC FIGURES, SCIENTISTS, AND POLICYMAKERS IN COMMUNICATING THE NEED FOR CONTINUED RESEARCH TO DEVELOP NEW METHODS OF PREVENTION AND TREATMENT, AND A CURE FOR HIV. RAISING HIV AWARENESS ACROSS PLATFORMSAMFAR FREQUENTLY SPOTLIGHTS INFORMATION ABOUT HIV AND OTHER HEALTH CHALLENGES ACROSS DIFFERENT PLATFORMS TO REACH DIVERSE AUDIENCES.AMFAR PRODUCES PERIODICALS IN BOTH PRINT AND DIGITAL FORMATS, INCLUDING ITS NEWSLETTER, INNOVATIONS, DISTRIBUTED TO ABOUT 15,500 PEOPLE, AND A MONTHLY E-MAIL NEWSLETTER, INSIGHTS, DISTRIBUTED TO APPROXIMATELY 24,500 RECIPIENTS. THE FOUNDATION'S WEBSITEWWW.AMFAR.ORGFEATURES NEWS, INTERVIEWS, AND ORIGINAL ARTICLES COVERING HIV RESEARCH, POLICY, THE GLOBAL EPIDEMIC, AND AMFAR PROGRAMS AND ACTIVITIES. THE WEBSITE ATTRACTS AN AVERAGE OF 27,433 MONTHLY VISITS. AMFAR CREATES AND DISTRIBUTES REPORTS, PRESS RELEASES, AND UPDATES ON MAJOR HIV/AIDS ISSUES AND CONDUCTS PUBLIC SERVICE ADVERTISING CAMPAIGNS THAT HAVE BEEN INSTRUMENTAL IN EDUCATING POLICYMAKERS, HEALTHCARE PROFESSIONALS, PEOPLE LIVING WITH HIV/AIDS, AND THE PUBLIC. AMFAR'S PUBLIC INFORMATION TEAM ALSO WORKS CLOSELY WITH THE PUBLIC POLICY OFFICE AND TREAT ASIA STAFF (SEE ABOVE) TO PRODUCE A WIDE RANGE OF ISSUE BRIEFS, FACTS SHEETS, INFOGRAPHICS, AND REPORTS.FOR WORLD AIDS DAY 2024, AMFAR PARTNERED WITH MAC VIVA GLAM TO HOST A RECEPTION AND PANEL DISCUSSION TITLED "HIV/AIDS: HOW WE CAN ALL RISE TO THE CHALLENGE" ON DECEMBER 4, 2024, IN NEW YORK CITY. THE MODERATED DISCUSSION COVERED HIV CURE RESEARCH, STIGMA, AND THE ROLE OF YOUNGER PEOPLE IN ADVOCACY EFFORTS. PANELISTS INCLUDED AMFAR'S NEWLY APPOINTED VICE PRESIDENT OF RESEARCH, ANDREA GRAMATICA, PHD; ROBERT PITTS, MD, MEDICAL DIRECTOR, HIV PREVENTION AND PRIDE CENTER AT NYC HEALTH + HOSPITALS/BELLEVUE; AND KIARA ST. JAMES, CO-FOUNDER AND EXECUTIVE DIRECTOR OF NEW YORK TRANSGENDER ADVOCACY GROUP.THROUGHOUT THE YEAR, AMFAR ROLLED OUT A SOCIAL MEDIA CAMPAIGN, FACTS FOR LIFE, THAT EDUCATED FOLLOWERS ABOUT A RANGE OF HIV-RELATED TOPICS: RESEARCH, TREATMENT, TRANSMISSION RISK, PREP AND OTHER PREVENTION TOOLS, AND CURE RESEARCH, AMONG OTHERS. IN JUNE 2025, AMFAR EXHIBITED AT THE 29TH ANNUAL BROOKLYN PRIDE MULTICULTURAL FESTIVAL IN BROOKLYN, NEW YORK, TO HELP RAISE AWARENESS ABOUT HIV/AIDS AND THE VITAL WORK THE ORGANIZATION DOES. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $1,963,199 | ExpenseAmt |
| Grant | $30,001 | GrantAmt |
| Revenue | $0 | RevenueAmt |
| Desc | PUBLIC POLICYAMFAR'S PUBLIC POLICY OFFICE UNDERSCORES URGENT HIV PUBLIC POLICY ISSUES BY MAKING DATA INTERPRETABLE AND ACCESSIBLE FOR ADVOCACY. THE MISSION OF THE FOUNDATION'S POLICY PROGRAM IS TO: 1. SUPPORT EVIDENCE-BASED HIV POLICIES; 2. ADVOCATE FOR INCREASED GLOBAL, DOMESTIC, AND RESEARCH HIV DOLLARS; AND 3. ENSURE THAT EFFORTS TO END HIV ADDRESS OLD AND NEW THREATS. THE POLICY OFFICE ACCOMPLISHES THESE OBJECTIVES BY PUBLISHING IN MEDICAL JOURNALS AND GARNERING MEDIA ATTENTION, AS WELL AS THE ATTENTION OF CONGRESSIONAL MEMBERS AND OFFICES. IN FY25, THE POLICY OFFICE'S SCIENTIFIC PUBLICATIONS INCLUDED IN THREE ARTICLES IN TWO HIGHLY COMPETITIVE SOUGHT-AFTER MEDICAL JOURNALS [THE LANCET AND THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA)]. ENDING THE HIV EPIDEMIC AND OTHER HEALTH CHALLENGES IN THE U.S.THROUGHOUT THE YEAR, AMFAR MET WITH MEMBERS OF CONGRESS, SENATE AND HOUSE COMMITTEES, AND OTHER GOVERNMENT REPRESENTATIVES TO PROMOTE AN EVIDENCED-BASED RESPONSE TO THE U.S. HIV EPIDEMIC AND DISCUSS POLICY INITIATIVES. IN PARTICULAR, POLICY STAFF DEVELOPED AND SHARED RAPID-RESPONSE INFORMATION WITH STAKEHOLDERS ABOUT BEST PRACTICES IN THE DOMESTIC HIV RESPONSE, HIGHLIGHTING DOCUMENTED SUCCESSES OF THE ENDING THE HIV EPIDEMIC INITIATIVE AND THE NATIONAL INSTITUTES OF HEALTH, FOR EXAMPLE.AMFAR FOCUSED MUCH OF ITS EFFORTS ON KEEPING DOMESTIC HIV FUNDING FOR RESEARCH AND SERVICES ON TRACK AND ADDRESSING THE ELIMINATION OF THE CDC'S HIV PREVENTION PROGRAMS, PRODUCING AN UNPRECEDENTED NUMBER OF ANALYSES ON THE POSITIVE IMPACT OF HEALTH RESEARCH AND PREVENTION PROGRAMS ON THE HIV EPIDEMIC. ONE AMFAR ANALYSIS SHOWING HOW CUTS TO CDC HIV PREVENTION WOULD INCREASE NEW INFECTIONS NOT ONLY RECEIVED MEDIA ATTENTION, BUT WAS USED BY MEMBERS OF CONGRESS TO JUSTIFY CONTINUING TO FUND HIV PREVENTION. THE REMAINING POLICY ANALYSES RELEASED BY THE POLICY OFFICE EMPHASIZED THE IMPORTANCE OF FUNDING HIV SCIENCE: IGNORING SCIENCE WILL WORSEN THE HIV EPIDEMIC IN THE U.S.; THE BEST INVESTMENT YOU DIDN'T KNOW YOU MADE: HOW NIH FUNDING FUELS INNOVATION AND ECONOMIC GROWTH; HIDDEN COSTS OF CAPPING NIH INDIRECT COSTS; PRESIDENT'S TRUMP HIV PLAN IS TOO VALUABLE TO LOSE; DOMESTIC FUNDING CONTRIBUTIONS TO HEALTH; AND WHEN GRANTS END, SO DO SCIENTIFIC BREAKTHROUGHS. IN MARCH 2025, POLICY STAFF ATTENDED THE CONFERENCE ON RETROVIRUSES AND INFECTIOUS DISEASES (CROI) TO DISCUSS THE ADMINISTRATION'S POLICIES AND IMPACTS ON HIV RESEARCH AT ACADEMIC INSTITUTIONS ACROSS THE COUNTRY. IN SEPTEMBER 2025, AMFAR'S POLICY OFFICE COAUTHORED A POLICY ANALYSIS PUBLISHED IN JAMA SHOWING THAT ESTIMATED HIV PREVENTION BUDGET CUTS WOULD RESULT IN 9,000 EXCESS INFECTIONS IN THE NEXT DECADE AND COST AN ADDITIONAL $4 BILLION. ADVOCACY WORK FOCUSED ON PRESENTATIONS TO AND COLLABORATIONS WITH HIV AND HEALTH-FOCUSED ORGANIZATIONS SUCH AS SOUTHERN AIDS COALITION, GEORGETOWN LAW'S O'NEILL INSTITUTE, HUMAN RIGHTS CAMPAIGN, FUNDERS CONCERNED ABOUT AIDS, AIDS UNITED, AND LAMBDA LEGAL, AMONG OTHERS. AMFAR'S POLICY OFFICE WAS ALSO ONE OF SEVERAL NATIONAL SPONSORS OF AIDSWATCH WHICH BRINGS HUNDREDS OF HIV ADVOCATES TO WASHINGTON, D.C., TO URGE MEMBERS OF CONGRESS TO CONTINUE TO FUND HIV RESEARCH AND PROGRAMS.ALONG WITH ITS FOCUS ON HIV, THE POLICY OFFICE PARTICIPATED IN DISCUSSIONS ON A RANGE OF TOPICS, FROM WOMEN'S HEALTH TO THE INCORPORATION OF TECHNOLOGY (INCLUDING AI) INTO PUBLIC HEALTH AND HEALTHCARE DELIVERY.ENSURING GLOBAL HEALTH ACCESSAMFAR MAINTAINS AN ACTIVE ROLE IN GLOBAL ADVOCACY AND POLICY INITIATIVES, AND, IN LIGHT OF A FEDERAL-LEVEL RETREAT FROM ESTABLISHED GLOBAL HEALTH PRIORITIES, POLICY STAFF PROVIDED DATA TO GOVERNMENT OFFICIALS ABOUT THE IMPORTANCE OF PEPFAR (THE U.S. PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF), WORKED WITH ADVOCATES TO ALLEVIATE THE IMPACT OF THE FUNDING CUTS, AND PARTICIPATED IN MONTHLY MEETINGS WITH THE BUSH INSTITUTE ON PEPFAR REAUTHORIZATION AND FUNDING. AMFAR WORKED WITH OTHER ADVOCACY ORGANIZATIONS TO PUSH BACK ON THE PROPOSED $400 MILLION RECISSION CUTS TO PEPFAR.THE POLICY OFFICE PRODUCED A REPORT AND A PUBLISHED ANALYSIS THAT RECEIVED WIDESPREAD MEDIA ATTENTION, AS WELL AS CONGRESSIONAL ATTENTION IN LIGHT OF HALTING THE PEPFAR PROGRAM (REPORT: IMPACT OF STOP WORK ORDERS FOR PEPFAR PROGRAMS; SCIENTIFIC PUBLICATION: EARLY IMPACTS OF THE PEPFAR STOP WORK ORDER: A RAPID ASSESSMENT). THE POLICY OFFICE SUPPORTED CIVIL SOCIETY ORGANIZATIONS TO UNDERSTAND THE IMPACT OF THE U.S. GOVERNMENT STOP-WORK ORDERS AND TERMINATION OF GRANTS. AMFAR PARTICIPATED IN A SAVE PEPFAR MEETING ORGANIZED BY HIV ACTIVISTS AND SUPPLIED DATA ON PEPFAR TO NUMEROUS RESEARCHERS TO SUPPORT THEIR MODELING AND ADVOCACY WORK. THE POLICY OFFICE SUPPORTED COMMUNITY ADVOCACY IN GLOBAL FUND COUNTRIES TO TRACK REALLOCATION AND REPRIORITIZATION PROCESSES IN THE FACE OF GLOBAL FUND FUNDING CUTS.AMFAR ALSO MET WITH UNAIDS OFFICIALS TO DISCUSS REVISING A GLOBAL AIDS STRATEGY FOR 2026 THROUGH 2030. OTHER HIGH-LEVEL MEETINGS FOCUSED ON GLOBAL GAG RULE RESEARCH AND GLOBAL PREP ACCESS.ADDITIONALLY, AMFAR PLAYS A KEY ROLE AS A TECHNICAL ASSISTANCE PROVIDER FOR IN-COUNTRY COMMUNITY-LED MONITORING EFFORTS IN SEVEN COUNTRIESSOUTH AFRICA, LESOTHO, MALAWI, UGANDA, HAITI, AND (WITH TREAT ASIA) INDIA AND INDONESIA. IN THIS ROLE, AMFAR ENGAGES WITH LOCAL ACTIVISTS AND DATA COLLECTION TEAMS TO ENSURE HIGH-QUALITY DATA ARE PRODUCED FOR HIV SERVICE QUALITY MONITORING AND ADVOCACY INITIATIVES. AMFAR COSPONSORED AN INTERNATIONAL STUDYTHE SCOPE (SUPPORT FOR COMMUNITY ORGANIZATIONS & PRIORITIES FOR EMPOWERMENT AND IMPACT) REPORTTHAT SHOWED GLOBAL FUND-SUPPORTED HIV SERVICE DELIVERY PROGRAMS PROFOUNDLY BENEFIT FROM LOCAL EXPERTISE AND LEADERSHIP. PUBLISHED IN AUGUST 2025, THE STUDY SURVEYED 317 COMMUNITY STAKEHOLDERS ACROSS 33 COUNTRIES AND CONDUCTED IN-DEPTH CONSULTATIONS FOR STUDY DESIGN AND COMMUNITY-BASED ASSESSMENTS. IN FY2025 PUBLIC POLICY OFFICE TEAM SERVED ON SEVERAL GLOBAL HIV BOARDS, INCLUDING THE PEPFAR SCIENTIFIC ADVISORY BOARD, THE NONPROFIT CONSTITUENCY OF THE GLOBAL FUND BOARD, THE BOARD FOR THE INTERNATIONAL AIDS SOCIETY, AND THE FUNDERS CONCERNED ABOUT AIDS BOARD. EMPOWERMENT THROUGH DATAAMFAR IS AT THE FOREFRONT OF DATA COLLECTION FOR ADVOCACY PURPOSES, FORTIFYING PUBLIC HEALTH RESPONSES WITH ACCURATE INFORMATION. IN ADDITION, AMFAR MAINTAINS A SUITE OF FREE INTERACTIVE DATABASES THAT ARE INVALUABLE RESOURCES FOR INDIVIDUALS AND ORGANIZATIONS WORKING TO SECURE AND MONITOR HIV-RELATED FUNDING AND TAILOR PROGRAMS TO MEET THE NEEDS OF CLIENTS. ADVOCATES FROM AROUND THE WORLD RELY ON THESE RESOURCES TO EASILY ACCESS DATA AND PREPARE ADVOCACY INITIATIVES. THE FIVE DATABASES ARE: PEPFAR MONITORING, EVALUATION, AND REPORTING (MER.AMFAR.ORG) PEPFAR COUNTRY/REGIONAL OPERATIONAL PLANS (COPSDATA.AMFAR.ORG) KEY POPULATIONS AND KEY POPULATION INVESTMENT FUND (KPIF) DATA PROJECT (KPDATA.AMFAR.ORG) ENDING THE HIV EPIDEMIC IN THE U.S. (EHE.AMFAR.ORG) OPIOID & HEATH INDICATORS DATABASE (OPIOID.AMFAR.ORG) AMPLIFYING EXPERTISEAMFAR PARTICIPATED IN NUMEROUS PRESENTATIONS AND PANELS AT MEETINGS AND CONFERENCES THROUGHOUT THE YEAR. IN DECEMBER 2024, POLICY STAFF FACILITATED AND SUPPORTED AMFAR CEO'S APPEARANCE AT A WHITE HOUSE PANEL TO DISCUSS LESSONS LEARNED FROM THE HIV MOVEMENT FOR THE POSSIBLE ESTABLISHMENTS OF A GLOBAL CANCER FUND. IN 2025, AMFAR HELPED LAUNCH THE GLOBAL CANCER FINANCING PLATFORM AND THE HIV/HPV EXPERT WORKING GROUP, BOTH OF WHICH HIGHLIGHT WOMEN'S CANCERS.AT THE INTERNATIONAL AIDS SOCIETY CONFERENCE ON HIV SCIENCE IN JULY 2025, AMFAR PUBLIC POLICY STAFF DELIVERED SIX PRESENTATIONS. AMONG THEM, GREG MILLETT, MPH, AMFAR VP AND DIRECTOR OF PUBLIC POLICY, ALONG WITH AGNES CHETTY OF THE WORLD HEALTH ORGANIZATION (WHO), CO-FACILITATED A SYMPOSIUM TITLED, "ARE INTEGRATION AND EQUITY AT ODDS?" THAT EXAMINED HOW ADDRESSING DIFFERENT, AND OFTEN-SILOED HEALTHCARE-BASED RESPONSES TO HIV MIGHT BE COMBINED IN AN ERA OF FUNDING DECREASES. IN ADDITION, DR. JENNIFER SHERWOOD PRESENTED RESEARCH ON HOW INCREASING CERVICAL CANCER SCREENING FOR WOMEN LIVING WITH HIV IMPROVES HEALTH OUTCOMES. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $1,963,199 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $30,001 | TotalOtherProgSrvcGrantAmt |
| Total Other Prog Srvc Revenue | $0 | TotalOtherProgSrvcRevenueAmt |
| Total Program Service Expenses | $24,111,935 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | Yes (1) | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | Yes (1) | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | Yes (1) | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (1) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | Yes (1) | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | Yes (1) | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (1) | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 120 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Employee | 71 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (1) | ForeignFinancialAccountInd |
| Foreign Country | TH | ForeignCountryCd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (1) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (1) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 14 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 14 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | Yes (1) | LocalChaptersInd |
| Policies Reference Chapters | Yes (1) | PoliciesReferenceChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | GA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | HI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Other Website | Yes (X) | OtherWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | SHAWN DAVIDSON | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 2128061600 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 120 WALL STREET 13TH FLOOR | AddressLine1Txt |
| City | NEW YORK | CityNm |
| State Abbreviation | NY | StateAbbreviationCd |
| ZIP | 100053908 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (30 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd | Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd |
|---|---|---|---|---|---|---|---|---|---|
| T RYAN GREENWALT | |||||||||
| CO-CHAIR | 1.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| KEVIN MCCLATCHY | |||||||||
| CO-CHAIR | 1.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| ROBERT L TRAYNHAM II | |||||||||
| SECRETARY | 1.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| DONALD DYE | |||||||||
| TREASURER, THRU MARCH 2025 | 1.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| JEFFREY SCHOENFELD | |||||||||
| TREASURER | 1.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | |||
| AMY ANDELSON | |||||||||
| TRUSTEE | 1.00 | Yes (X) | $0 | $0 | $0 | ||||
| GLEN ISAACSON | |||||||||
| TRUSTEE | 1.00 | Yes (X) | $0 | $0 | $0 | ||||
| MICHAEL LORBER | |||||||||
| TRUSTEE | 1.00 | Yes (X) | $0 | $0 | $0 | ||||
| ANTHONY MANCILLA | |||||||||
| TRUSTEE | 1.00 | Yes (X) | $0 | $0 | $0 | ||||
| ARON MARQUEZ | |||||||||
| TRUSTEE | 1.00 | Yes (X) | $0 | $0 | $0 | ||||
| LARRY MILSTEIN | |||||||||
| TRUSTEE | 1.00 | Yes (X) | $0 | $0 | $0 | ||||
| CINDY RACHOFSKY | |||||||||
| TRUSTEE | 1.00 | Yes (X) | $0 | $0 | $0 | ||||
| VINCENT A ROBERTI | |||||||||
| TRUSTEE | 1.00 | Yes (X) | $0 | $0 | $0 | ||||
| MERV SILVERMAN | |||||||||
| TRUSTEE | 1.00 | Yes (X) | $0 | $0 | $0 | ||||
| PHILL WILSON | |||||||||
| TRUSTEE | 1.00 | Yes (X) | $0 | $0 | $0 | ||||
| KEVIN FROST | |||||||||
| CHIEF EXECUTIVE OFFICER | 40.00 | Yes (X) | $543,683 | $0 | $133,884 | ||||
| BRADLEY JENSEN ASSISTANT | |||||||||
| TREASURER/CFO, THRU JULY 2025 | 40.00 | Yes (X) | $376,610 | $0 | $91,196 | ||||
| SEBASTIAN GHEITH | |||||||||
| GENERAL COUNSEL, ASST SECRETARY | 40.00 | Yes (X) | $201,976 | $0 | $101,497 | ||||
| SHAWN DAVIDSON CHIEF | |||||||||
| FINANCIAL AND OPERATING OFFICER | 40.00 | Yes (X) | $0 | $0 | $0 | ||||
| SHKENDIJE KABA | |||||||||
| ASSISTANT TREASURER, CONTROLLER | 40.00 | Yes (X) | $0 | $0 | $0 | ||||
| RONALD KIRK ASSISTANT TREASURER | |||||||||
| CONTROLLER, THRU JUNE 2025 | 40.00 | Yes (X) | $191,077 | $0 | $41,802 | ||||
| KYLE CLIFFORD | |||||||||
| VICE PRESIDENT OF DEVELOPMENT | 40.00 | $292,133 | $0 | $88,122 | Yes (X) | ||||
| ANNETTE SOHN | |||||||||
| VICE PRESIDENT, TREAT ASIA | 40.00 | $282,080 | $0 | $30,365 | Yes (X) | ||||
| GREGORIO MILLET | |||||||||
| VICE PRESIDENT, PUBLIC POLICY | 40.00 | $325,758 | $0 | $90,320 | Yes (X) | ||||
| ANTHONY ANCONA | |||||||||
| VICE PRESIDENT OF HUMAN RESOURCES | 40.00 | $211,292 | $0 | $82,399 | Yes (X) | ||||
| ANDREW MCINNES | |||||||||
| DIRECTOR, PUBLICATIONS | 40.00 | $197,892 | $0 | $81,179 | Yes (X) | ||||
| EMMA KOSTURA | |||||||||
| DIRECTOR, PHILANTHROPY | 40.00 | $142,196 | $0 | $76,657 | Yes (X) | ||||
| CHRISTOPHER FREDERICK | |||||||||
| SPECIAL EVENTS DIRECTOR | 40.00 | $196,451 | $0 | $68,362 | Yes (X) | ||||
| BENNAH SERFATY | |||||||||
| SENIOR DIRECTOR OF COMMUNICATIONS | 40.00 | $153,102 | $0 | $97,984 | Yes (X) | ||||
| JAMES SHAKLEFORD FORMER | |||||||||
| VP OF PUBLIC INFORMATION | 0.00 | $163,552 | $0 | $29,699 | Yes (X) | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $3,277,802 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $1,013,466 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 28 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | Yes (1) | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| RAFANELLI EVENTS MANAGEMENT INC | |||||
| 361 NEWBURY STREET 5TH FL | BOSTON | MA | 02115 | EVENT MANAGEMENT | $1,694,395 |
| AAB PRODUCTIONS INC | |||||
| 64 ALLEN ROAD 5TH FLOOR | NEW YORK | NY | 10002 | EVENT PRODUCTION | $473,600 |
| SANKY COMMUNICATIONS INC | |||||
| 360 W 31ST ST FL 6 | NEW YORK | NY | 10001 | DIRECT MAIL/RESPONSE CONSULTANTS | $462,898 |
| STEERPIKE PRODUCTIONS LLC | |||||
| 250 W 57TH ST 23RD FL | NEW YORK | NY | 10107 | EVENT PRODUCTION | $450,000 |
| TODD EVENT DESIGN | |||||
| 1174 QUAKER STREET | DALLAS | TX | 75207 | EVENT PRODUCTION | $368,502 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 17 | CntrctRcvdGreaterThan100KCnt |
| Federated Campaigns | $73,423 | FederatedCampaignsAmt |
| Fundraising | $29,733,448 | FundraisingAmt |
| Government Grants | $10,086,808 | GovernmentGrantsAmt |
| All Other Contributions | $8,278,206 | AllOtherContributionsAmt |
| Noncash Contributions | $423,536 | NoncashContributionsAmt |
| Total Contributions | $48,171,885 | TotalContributionsAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,204,687 | TotalRevenueColumnAmt |
| Exclusion | $1,204,687 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $50,122 | TotalRevenueColumnAmt |
| Exclusion | $50,122 | ExclusionAmt |
Gross Rents GrossRentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $85,460 | RealAmt |
Less Rental Expenses LessRentalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $0 | RealAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $85,460 | RealAmt |
Net Rental Income Or Loss NetRentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $85,460 | TotalRevenueColumnAmt |
| Exclusion | $85,460 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $6,412,661 | SecuritiesAmt |
| Other | $33,000 | OtherAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $5,963,901 | SecuritiesAmt |
| Other | $39,349 | OtherAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $448,760 | SecuritiesAmt |
| Other | -$6,349 | OtherAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $442,411 | TotalRevenueColumnAmt |
| Exclusion | $442,411 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $1,124,500 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $29,733,448 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $16,304,670 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$15,180,170 | TotalRevenueColumnAmt |
| Exclusion | -$15,180,170 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gaming Gross Income | $3,030 | GamingGrossIncomeAmt |
| Gaming Direct Expenses | $0 | GamingDirectExpensesAmt |
Net Income From Gaming NetIncomeFromGamingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $3,030 | TotalRevenueColumnAmt |
| Exclusion | $3,030 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Sales Of Inventory | $6,609 | GrossSalesOfInventoryAmt |
| Cost Of Goods Sold | $477 | CostOfGoodsSoldAmt |
Net Income Or Loss NetIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $6,132 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $6,132 | RelatedOrExemptFuncIncomeAmt |
Other Revenue Misc OtherRevenueMiscGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | MISCELLANEOUS INCOME | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $387 | TotalRevenueColumnAmt |
| Exclusion | $387 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $387 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $34,783,944 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $6,132 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | -$13,394,073 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,458,236 | TotalAmt |
| Program Services | $2,458,236 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,927,375 | TotalAmt |
| Program Services | $3,927,375 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,227,862 | TotalAmt |
| Program Services | $2,254,592 | ProgramServicesAmt |
| Management And General | $433,409 | ManagementAndGeneralAmt |
| Fundraising | $539,861 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,832,188 | TotalAmt |
| Program Services | $3,731,243 | ProgramServicesAmt |
| Management And General | $629,084 | ManagementAndGeneralAmt |
| Fundraising | $1,471,861 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $370,930 | TotalAmt |
| Program Services | $228,891 | ProgramServicesAmt |
| Management And General | $64,869 | ManagementAndGeneralAmt |
| Fundraising | $77,170 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,070,570 | TotalAmt |
| Program Services | $1,296,701 | ProgramServicesAmt |
| Management And General | $344,059 | ManagementAndGeneralAmt |
| Fundraising | $429,810 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $570,431 | TotalAmt |
| Program Services | $357,000 | ProgramServicesAmt |
| Management And General | $71,718 | ManagementAndGeneralAmt |
| Fundraising | $141,713 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $70,884 | TotalAmt |
| Program Services | $64,706 | ProgramServicesAmt |
| Management And General | $6,146 | ManagementAndGeneralAmt |
| Fundraising | $32 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $151,087 | TotalAmt |
| Management And General | $151,087 | ManagementAndGeneralAmt |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $437,122 | TotalAmt |
| Fundraising | $437,122 | FundraisingAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $189,622 | TotalAmt |
| Management And General | $189,622 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,582,161 | TotalAmt |
| Program Services | $500,471 | ProgramServicesAmt |
| Management And General | $285,737 | ManagementAndGeneralAmt |
| Fundraising | $795,953 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $220,590 | TotalAmt |
| Program Services | $133,489 | ProgramServicesAmt |
| Management And General | $4,470 | ManagementAndGeneralAmt |
| Fundraising | $82,631 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $54,669 | TotalAmt |
| Program Services | $41,401 | ProgramServicesAmt |
| Management And General | $10,138 | ManagementAndGeneralAmt |
| Fundraising | $3,130 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $215,959 | TotalAmt |
| Program Services | $142,195 | ProgramServicesAmt |
| Management And General | $30,416 | ManagementAndGeneralAmt |
| Fundraising | $43,348 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,670,454 | TotalAmt |
| Program Services | $1,098,793 | ProgramServicesAmt |
| Management And General | $239,435 | ManagementAndGeneralAmt |
| Fundraising | $332,226 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,212,853 | TotalAmt |
| Program Services | $373,067 | ProgramServicesAmt |
| Management And General | $3,640 | ManagementAndGeneralAmt |
| Fundraising | $836,146 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $457,085 | TotalAmt |
| Program Services | $444,076 | ProgramServicesAmt |
| Management And General | $11,778 | ManagementAndGeneralAmt |
| Fundraising | $1,231 | FundraisingAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $39,906 | TotalAmt |
| Program Services | $26,249 | ProgramServicesAmt |
| Management And General | $5,720 | ManagementAndGeneralAmt |
| Fundraising | $7,937 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $497,306 | TotalAmt |
| Program Services | $327,119 | ProgramServicesAmt |
| Management And General | $71,281 | ManagementAndGeneralAmt |
| Fundraising | $98,906 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $223,073 | TotalAmt |
| Program Services | $146,733 | ProgramServicesAmt |
| Management And General | $31,974 | ManagementAndGeneralAmt |
| Fundraising | $44,366 | FundraisingAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| PROGRAM MATERIALS | $5,052,954 | $5,052,954 | ||
| SUBSCRIPTION & DUES | $563,322 | $376,685 | $75,887 | $110,750 |
| PROGRAM TECHNICAL SUPPO | $528,383 | $528,383 | ||
| INTERNET ACCESS | $417,364 | $92,119 | $19,963 | $305,282 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,299,163 | TotalAmt |
| Program Services | $509,457 | ProgramServicesAmt |
| Management And General | $248,696 | ManagementAndGeneralAmt |
| Fundraising | $541,010 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $33,341,549 | TotalAmt |
| Program Services | $24,111,935 | ProgramServicesAmt |
| Management And General | $2,929,129 | ManagementAndGeneralAmt |
| Fundraising | $6,300,485 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,914,515 | BOYAmt |
| EOY | $2,741,510 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,128,104 | BOYAmt |
| EOY | $1,514,582 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $70,732 | BOYAmt |
| EOY | $534,613 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,146,670 | BOYAmt |
| EOY | $6,877,850 | EOYAmt |
Inventories For Sale Or Use InventoriesForSaleOrUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $92,130 | BOYAmt |
| EOY | $90,975 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,763,416 | BOYAmt |
| EOY | $1,957,091 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $7,945,073 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $6,229,173 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,062,644 | BOYAmt |
| EOY | $1,715,900 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $36,477,231 | BOYAmt |
| EOY | $38,724,426 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,698,590 | BOYAmt |
| EOY | $3,833,893 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $53,354,032 | BOYAmt |
| EOY | $57,990,840 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,125,286 | BOYAmt |
| EOY | $7,545,620 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $32,446 | BOYAmt |
| EOY | $861,093 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,592,061 | BOYAmt |
| EOY | $8,057,123 | EOYAmt |
Escrow Account Liability EscrowAccountLiabilityGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $18,000 | BOYAmt |
| EOY | $0 | EOYAmt |
Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,398,459 | BOYAmt |
| EOY | $0 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,374,174 | BOYAmt |
| EOY | $4,455,590 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $19,540,426 | BOYAmt |
| EOY | $20,919,426 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $31,263,900 | BOYAmt |
| EOY | $33,384,965 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,549,706 | BOYAmt |
| EOY | $3,686,449 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $33,813,606 | BOYAmt |
| EOY | $37,071,414 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $53,354,032 | BOYAmt |
| EOY | $57,990,840 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | $1,442,395 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $2,185,289 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | -$369,876 | OtherChangesInNetAssetsAmt |
| Info In Schedule O Part XII | Yes (X) | InfoInScheduleOPartXIIInd |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $28,070,013 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $43,028,236 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $42,163,024 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $39,707,167 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $48,171,885 | CurrentTaxYearAmt |
| Total | $201,140,325 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $28,070,013 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $43,028,236 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $42,163,024 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $39,707,167 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $48,171,885 | CurrentTaxYearAmt |
| Total | $201,140,325 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $29,985 | SubstantialContributorsTotAmt |
| Public Support Total170 | $201,110,340 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,025,000 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,328,141 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $1,301,913 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $1,359,141 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $1,340,269 | CurrentTaxYearAmt |
| Total | $6,354,464 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $7,858 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $18,851 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $115 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $694 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $387 | CurrentTaxYearAmt |
| Total | $27,905 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $207,522,694 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $70,598 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.96910 | PublicSupportCY170Pct |
| Public Support PY170 | 0.96220 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Form990 Schedule A Part VI Form990ScheduleAPartVIGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: | FormAndLineReferenceDesc |
| Explanation | MISCELLANEOUS - 2020 AMOUNT: $ 6,555. 2022 AMOUNT: $ 115. 2023 AMOUNT: $ 694. 2024 AMOUNT: $ 387. STORE SALES - 2020 AMOUNT: $ 1,303. IRS TAX REFUND - 2021 AMOUNT: $ 18,851. | ExplanationTxt |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteers | 0 | VolunteersInd |
| Paid Staff Or Management | Yes (1) | PaidStaffOrManagementInd |
| Media Advertisements | 0 | MediaAdvertisementsInd |
| Mailings Members | 0 | MailingsMembersInd |
| Publications Or Broadcast | 0 | PublicationsOrBroadcastInd |
| Grants Other Organizations | 0 | GrantsOtherOrganizationsInd |
| Direct Contact Legislators | 0 | DirectContactLegislatorsInd |
| Rallies Demonstrations | 0 | RalliesDemonstrationsInd |
| Other Activities | Yes (1) | OtherActivitiesInd |
| Other Activities | $176,541 | OtherActivitiesAmt |
| Total Lobbying Expenditures | $176,541 | TotalLobbyingExpendituresAmt |
| Not Described Section501c3 | 0 | NotDescribedSection501c3Ind |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II-B, LINE 1: | FormAndLineReferenceDesc |
| Explanation | THE FOUNDATION FOR AIDS RESEARCH DEVELOPED AN ACTION AGENDA TO END AIDS THAT IDENTIFIED CRITICAL DECISIONS THAT NEED TO BE MADE TO ADVANCE EVIDENCE BASED AIDS POLICIES. WE CREATED A VARIETY OF ISSUE BRIEFS ON TOPICS SUCH AS THE POTENTIAL IMPACT OF VARIOUS BUDGET SCENARIOS ON GLOBAL HEALTH SERVICES, AND POLICY PRIORITIES TO ADDRESS THE HIV EPIDEMIC AMONG GAY MEN IN THE US. THESE ISSUE BRIEFS WERE SHARED WITH CAPITOL HILL STAFF AND MEMBERS OF THE ADMINISTRATION. AMFAR MET REGULARLY WITH STAFF TO MEMBERS OF CONGRESS AND WITH ADMINISTRATION STAFF, AND WE PROVIDED INPUT TO THE ADMINISTRATION ON DEVELOPMENT OF THE PEPFAR BLUEPRINT FOR AN AIDS FREE GENERATION. AMFAR SPONSORED SEVERAL BRIEFINGS ON CAPITOL HILL ON AIDS POLICY AND RESEARCH ISSUES. AMFAR USES THESE BRIEFINGS AS AN EDUCATIONAL TOOL. | ExplanationTxt |
Schedule D IRS990ScheduleD
Held Works Art HeldWorksArtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Assets Included | $85,042 | AssetsIncludedAmt |
Collection Used Other Purposes CollectionUsedOtherPurposesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Collection Used Other Purposes | Yes (X) | CollectionUsedOtherPurposesInd |
| Other Purposes | DONATED ITEMS, INVENTORY ETC. | OtherPurposesDesc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Solicited Assets Sale | Yes (1) | SolicitedAssetsSaleInd |
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $829,357 | BeginningYearBalanceAmt |
| Contributions | $0 | ContributionsAmt |
| Investment Earnings Or Losses | $11,743 | InvestmentEarningsOrLossesAmt |
| End Year Balance | $841,100 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $744,314 | BeginningYearBalanceAmt |
| Contributions | $750 | ContributionsAmt |
| Investment Earnings Or Losses | $84,293 | InvestmentEarningsOrLossesAmt |
| End Year Balance | $829,357 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $702,275 | BeginningYearBalanceAmt |
| Contributions | $6,450 | ContributionsAmt |
| Investment Earnings Or Losses | $35,589 | InvestmentEarningsOrLossesAmt |
| End Year Balance | $744,314 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $785,615 | BeginningYearBalanceAmt |
| Contributions | $4,700 | ContributionsAmt |
| Investment Earnings Or Losses | -$88,040 | InvestmentEarningsOrLossesAmt |
| End Year Balance | $702,275 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $731,736 | BeginningYearBalanceAmt |
| Contributions | $5,380 | ContributionsAmt |
| Investment Earnings Or Losses | $48,499 | InvestmentEarningsOrLossesAmt |
| End Year Balance | $785,615 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated Balance EOY | 0.00000 | BoardDesignatedBalanceEOYPct |
| Prmnnt Endowment Balance EOY | 0.48000 | PrmnntEndowmentBalanceEOYPct |
| Term Endowment Balance EOY | 0.52000 | TermEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | 0 | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | 0 | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $2,723,143 | OtherCostOrOtherBasisAmt |
| Depreciation | $2,313,008 | DepreciationAmt |
| Book Value | $410,135 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $868,500 | OtherCostOrOtherBasisAmt |
| Depreciation | $865,470 | DepreciationAmt |
| Book Value | $3,030 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $4,353,430 | OtherCostOrOtherBasisAmt |
| Depreciation | $3,050,695 | DepreciationAmt |
| Book Value | $1,302,735 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $1,715,900 | TotalBookValueLandBuildingsAmt |
Other Assets Org OtherAssetsOrgGrp (4 entries)
| DescDesc | Book ValueBookValueAmt |
|---|---|
| SECURITY DEPOSITS | $58,081 |
| RIGHT OF USE ASSETS | $3,146,565 |
| DEBT SERVICE RESERVE | $603,355 |
| EMPLOYEE ADVANCES | $25,892 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Other Assets | $3,833,893 | TotalBookValueOtherAssetsAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)
| DescDesc | AmtAmt |
|---|---|
| SEC. 457 RETIREMENT LIABILITY | $603,355 |
| OPERATING LEASES | $3,852,235 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $4,455,590 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $36,716,577 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | $2,185,289 | NetUnrealizedGainsInvstAmt |
| Donated Services And Use Fclts | $15,600 | DonatedServicesAndUseFcltsAmt |
| Other Revenue | $6,826 | OtherRevenueAmt |
| Revenue Not Reported | $2,207,715 | RevenueNotReportedAmt |
| Revenue Subtotal | $34,508,862 | RevenueSubtotalAmt |
| Investment Expenses Not Incld | $189,622 | InvestmentExpensesNotIncldAmt |
| Other Revenues Not Included | $85,460 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | $275,082 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $34,783,944 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $33,458,769 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $15,600 | DonatedServicesUseFcltsAmt |
| Other Expenses Included | $410,534 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $426,134 | ExpensesNotReportedAmt |
| Expenses Subtotal | $33,032,635 | ExpensesSubtotalAmt |
| Investment Expenses Not Incld2 | $189,622 | InvestmentExpensesNotIncld2Amt |
| Other Expenses Not Included | $119,292 | OtherExpensesNotIncludedAmt |
| Expenses Not Rpt Fincl Stmt | $308,914 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $33,341,549 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (7 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART III, LINE 4: | AMFAR SOLICITS ARTWORK FOR OUR EVENT AUCTIONS ARTWORK MAY BE DONATED OUTRIGHT, ON CONSIGNMENT OR SOMETIMES AMFAR PURCHASES THE PIECE IF IT CAN BE AUCTIONED WITH A LARGE ENOUGH RETURN. SOME ARE OUTRIGHT DONATIONS TO BE AUCTIONED AND SOME ARE PROVIDED ON CONSIGNMENT FOR THE AUCTION. |
| PART V, LINE 4: | AMFAR'S ENDOWMENT FUND IS INTENDED TO FUND THE VARIOUS GENERAL RESEARCH PROGRAMS THE ORGANIZATION SPONSORS. |
| PART X, LINE 2: | AMFAR RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT AMFAR HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. AMFAR IS NO LONGER SUBJECT TO EXAMINATIONS BY THE APPLICABLE TAXING JURISDICTIONS FOR PERIODS PRIOR TO 2022. |
| PART XI, LINE 2D - OTHER ADJUSTMENTS: | COST OF GOODS SOLD REPORTED ON PART VIII, LINE 10B 477. RECLASS OF SALE OF FIXED ASSETS REPORTED ON PART VIII, LINE 7A 6,349. |
| PART XI, LINE 4B - OTHER ADJUSTMENTS: | RECLASS OF SUBLEASE RENTAL INCOME TO PART VIII, LINE 6A 85,460. |
| PART XII, LINE 2D - OTHER ADJUSTMENTS: | COST OF GOODS SOLD REPORTED ON PART VIII, LINE 10B 477. WRITE OFF OF UNCOLLECTIBLE PLEDGES 403,708. RECLASS OF SALE OF FIXED ASSETS REPORTED ON PART VIII, LINE 7A 6,349. |
| PART XII, LINE 4B - OTHER ADJUSTMENTS: | RECLASS OF SUBLEASE RENTAL INCOME TO PART VIII, LINE 6A 85,460. OVERACCRUAL OF GRANT EXPENSES, NOT REFUNDED 33,832. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | 0 | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (6 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| EAST ASIA AND THE PACIFIC | 1 | 13 | PROGRAM SERVICES | THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING | $1,937,681 |
| SUB-SAHARAN AFRICA | 0 | 0 | GRANTMAKING | $89,581 | |
| EAST ASIA AND THE PACIFIC | 0 | 0 | GRANTMAKING | $2,506,196 | |
| SOUTH ASIA | 0 | 0 | GRANTMAKING | $200,002 | |
| EUROPE (INCLUDING ICELAND & GREENLAND) | 0 | 0 | GRANTMAKING | $1,131,596 | |
| EUROPE (INCLUDING ICELAND & GREENLAND) | 0 | 0 | PROGRAM SERVICES | THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING | $10,013,874 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 1 | SubtotalOfficesCnt |
| Subtotal Employees | 13 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 1 | TotalOfficeCnt |
| Total Employee | 13 | TotalEmployeeCnt |
| Subtotal Spent | $15,878,930 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $15,878,930 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (49 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Non Cash AssistanceNonCashAssistanceAmt |
|---|---|---|---|---|
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $634,454 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $252,890 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $228,294 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | RESEARCH | $212,672 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | RESEARCH | $113,941 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $112,422 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $96,345 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | RESEARCH | $89,998 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $83,745 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $79,013 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | RESEARCH | $64,970 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $60,050 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $37,692 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $35,241 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $33,496 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $26,880 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $26,613 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $26,543 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $23,465 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $19,840 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $18,700 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $18,660 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $18,000 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $17,500 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $17,410 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $16,020 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $15,000 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $12,000 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $12,000 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $12,000 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $12,000 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $8,540 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $8,500 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $7,940 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $7,660 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $7,500 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $6,911 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $6,375 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $6,300 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $6,150 | WIRE TRANSFER | $0 |
| EAST ASIA AND THE PACIFIC | TREAT ASIA | $5,925 | WIRE TRANSFER | $0 |
| EUROPE | RESEARCH | $588,161 | WIRE TRANSFER | $0 |
| EUROPE | RESEARCH | $286,393 | WIRE TRANSFER | $0 |
| EUROPE | RESEARCH | $219,542 | WIRE TRANSFER | $0 |
| EUROPE | RESEARCH | $37,500 | WIRE TRANSFER | $0 |
| SOUTH ASIA | TREAT ASIA | $152,312 | WIRE TRANSFER | $0 |
| SOUTH ASIA | TREAT ASIA | $31,641 | WIRE TRANSFER | $0 |
| SOUTH ASIA | TREAT ASIA | $12,600 | WIRE TRANSFER | $0 |
| SUB-SAHARAN AFRICA | RESEARCH | $89,581 | WIRE TRANSFER | $0 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 49 | Total501c3OrgCnt |
| Total Other Org | 0 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | FOREIGN ACTIVITIES INTERNATIONAL ORGANIZATIONS ARE RECOMMENDED FOR FUNDING BASED UPON THE RESULTS OF COMMUNITY-BASED PEER REVIEW AND/OR PROGRAM STAFF ASSESSMENT OF PROPOSAL MERIT AND ORGANIZATION CAPACITY TO UNDERTAKE PROPOSED PROJECTS THAT ARE CHARITABLE IN PURPOSE, PRE-AWARD DUE-DILIGENCE FOR NEW INTERNATIONAL GRANTEES INCLUDES REVIEW OF ORGANIZATION DOCUMENTS AND REGISTRATIONS TO VERIFY THAT THE ORGANIZATION OPERATES FOR A CHARITABLE PURPOSE AND THAT BASIC CAPACITY FOR PROJECT OVERSIGHT AND GOVERNANCE HAS BEEN ESTABLISHED. ALL INTERNATIONAL GRANTEES ARE REQUIRED TO REPORT SEMI-ANNUALLY ON PROJECT PROGRESS AND EXPENDITURES; CONTINUED REPORTING IS REQUIRED UNTIL SUCH TIME AS GRANT FUNDS ARE EXPENDED IN FULL. REPORTS ARE REVIEWED BY ADMINISTRATIVE AND PROGRAM STAFF. ADDITIONAL OVERSIGHT IS PROVIDED AS NECESSARY BY MEANS OF ONGOING, INFORMAL CONTACT WITH STEPS REGARDING PROGRESS AND TECHNICAL ISSUES AND SITE VISITS WHERE FEASIBLE. INTERNATIONAL RESEARCH GRANT RECIPIENTS SUBMIT AN INTERIM AND A FINAL PROGRESS REPORT IN ADDITION TO EXPENDITURES REPORTS DUE FOLLOWING THE ENDS OF THE 2ND, 3RD AND FINAL QUARTERS OF THE PERFORMANCE PERIOD. FOREIGN ACTIVITIES - PART I, LINE 3, COLUMN D: THE FOUNDATION FOR AIDS RESEARCH CONDUCTS MANY OF ITS GRANT-MAKING PROGRAM SERVICES (SEE PART III OF FORM 990) IN U.S AND FOREIGN JURISDICTIONS. IN COLUMN D, THE ORGANIZATION HAS REPORTED THE BASIC PROGRAM THESE GRANTS SUPPORT; PLEASE REFER TO PART III FOR MORE INFORMATION ABOUT THESE PROGRAMS/INITIATIVES. FOREIGN ACTIVITIES - STATUS OF GRANTEES THE FOUNDATION FOR AIDS RESEARCH SUPPORTS MANY NON-U.S ORGANIZATIONS IN THE FIGHT AGAINST AIDS AND HIV-RELATED DISEASES. FOR PURPOSES OF SCHEDULE F, PART II, LINE 2 - ALL CHARITIES SUPPORTED ARE PRESUMED TO BE THE EQUIVALENT OF U.S CHARITIES. |
| PART I, LINE 3: | THE ORGANIZATION USES THE ACCRUAL METHOD TO ACCOUNT FOR EXPENDITURES. |
Schedule G IRS990ScheduleG
| Field | Value | IRS element (for citing) |
|---|---|---|
| Mail Solicitations | Yes (X) | MailSolicitationsInd |
| Email Solicitations | Yes (X) | EmailSolicitationsInd |
| Phone Solicitations | Yes (X) | PhoneSolicitationsInd |
| Solicitation Of Non Govt Grants | Yes (X) | SolicitationOfNonGovtGrantsInd |
| Solicitation Of Govt Grants | Yes (X) | SolicitationOfGovtGrantsInd |
| Special Fundraising Events | Yes (X) | SpecialFundraisingEventsInd |
| Agrmt Prof Fundraising Acty | Yes (1) | AgrmtProfFundraisingActyInd |
Fundraiser Activity Info FundraiserActivityInfoGrp (3 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | ActivityActivityTxt | Fundraiser Control Of FundsFundraiserControlOfFundsInd | Gross ReceiptsGrossReceiptsAmt | Retained By ContractorRetainedByContractorAmt | Net To OrganizationNetToOrganizationAmt |
|---|---|---|---|---|---|---|---|---|
| AAB PRODUCTIONS | ||||||||
| 387 GRAND STREET SUITE K705 | NEW YORK | NY | 10002 | SPECIAL EVENT PRODUCTION | 0 | $18,103,549 | $168,500 | $17,935,049 |
| SANKY COMMUNICATIONS INC | ||||||||
| 360 W 31ST STREET FLOOR 6 | NEW YORK | NY | 10001 | DIRECT MAIL DIRECT RESPONSE CONSULTING | 0 | $993,005 | $233,479 | $759,526 |
| ALLEGIANCE FUNDRAISING LLC | ||||||||
| 3064 49TH STREET SOUTH | FARGO | ND | 58104 | DIRECT MAIL DIRECT RESPONSE CONSULTING | 0 | $156,982 | $35,143 | $121,839 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Gross Receipts | $19,253,536 | TotalGrossReceiptsAmt |
| Total Retained By Contractors | $437,122 | TotalRetainedByContractorsAmt |
| Total Net To Organization | $18,816,414 | TotalNetToOrganizationAmt |
| Licensed States | AL | LicensedStatesCd |
| Licensed States | AK | LicensedStatesCd |
| Licensed States | AZ | LicensedStatesCd |
| Licensed States | AR | LicensedStatesCd |
| Licensed States | CA | LicensedStatesCd |
| Licensed States | CO | LicensedStatesCd |
| Licensed States | CT | LicensedStatesCd |
| Licensed States | DE | LicensedStatesCd |
| Licensed States | FL | LicensedStatesCd |
| Licensed States | GA | LicensedStatesCd |
| Licensed States | HI | LicensedStatesCd |
| Licensed States | ID | LicensedStatesCd |
| Licensed States | IL | LicensedStatesCd |
| Licensed States | IN | LicensedStatesCd |
| Licensed States | IA | LicensedStatesCd |
| Licensed States | KS | LicensedStatesCd |
| Licensed States | KY | LicensedStatesCd |
| Licensed States | LA | LicensedStatesCd |
| Licensed States | ME | LicensedStatesCd |
| Licensed States | MD | LicensedStatesCd |
| Licensed States | MA | LicensedStatesCd |
| Licensed States | MI | LicensedStatesCd |
| Licensed States | MN | LicensedStatesCd |
| Licensed States | MS | LicensedStatesCd |
| Licensed States | MO | LicensedStatesCd |
| Licensed States | MT | LicensedStatesCd |
| Licensed States | NE | LicensedStatesCd |
| Licensed States | NH | LicensedStatesCd |
| Licensed States | NJ | LicensedStatesCd |
| Licensed States | NM | LicensedStatesCd |
| Licensed States | NY | LicensedStatesCd |
| Licensed States | NC | LicensedStatesCd |
| Licensed States | ND | LicensedStatesCd |
| Licensed States | OH | LicensedStatesCd |
| Licensed States | OK | LicensedStatesCd |
| Licensed States | OR | LicensedStatesCd |
| Licensed States | PA | LicensedStatesCd |
| Licensed States | RI | LicensedStatesCd |
| Licensed States | SC | LicensedStatesCd |
| Licensed States | SD | LicensedStatesCd |
| Licensed States | TN | LicensedStatesCd |
| Licensed States | UT | LicensedStatesCd |
| Licensed States | VT | LicensedStatesCd |
| Licensed States | VA | LicensedStatesCd |
| Licensed States | WA | LicensedStatesCd |
| Licensed States | WV | LicensedStatesCd |
| Licensed States | WI | LicensedStatesCd |
| Licensed States | WY | LicensedStatesCd |
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | CANNES GALA | Event1Nm |
| Gross Receipts Event1 | $14,692,353 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $14,274,353 | CharitableContriEvent1Amt |
| Gross Revenue Event1 | $418,000 | GrossRevenueEvent1Amt |
| Rent Facility Costs Event1 | $1,151,039 | RentFacilityCostsEvent1Amt |
| Food And Beverage Event1 | $689,939 | FoodAndBeverageEvent1Amt |
| Entertainment Event1 | $1,548,591 | EntertainmentEvent1Amt |
| Other Direct Expenses Event1 | $4,564,236 | OtherDirectExpensesEvent1Amt |
| Event2 | DALLAS TWO BY TWO | Event2Nm |
| Gross Receipts Event2 | $5,800,664 | GrossReceiptsEvent2Amt |
| Charitable Contri Event2 | $5,542,664 | CharitableContriEvent2Amt |
| Gross Revenue Event2 | $258,000 | GrossRevenueEvent2Amt |
| Rent Facility Costs Event2 | $475,374 | RentFacilityCostsEvent2Amt |
| Food And Beverage Event2 | $254,420 | FoodAndBeverageEvent2Amt |
| Entertainment Event2 | $196,642 | EntertainmentEvent2Amt |
| Other Direct Expenses Event2 | $1,048,109 | OtherDirectExpensesEvent2Amt |
| Other Events Total | 3 | OtherEventsTotalCnt |
| Gross Receipts Other Events | $10,364,931 | GrossReceiptsOtherEventsAmt |
| Charitable Contri Other Events | $9,916,431 | CharitableContriOtherEventsAmt |
| Gross Revenue Other Events | $448,500 | GrossRevenueOtherEventsAmt |
| Food And Beverage Other Events | $682,934 | FoodAndBeverageOtherEventsAmt |
| Entertainment Other Events | $1,243,096 | EntertainmentOtherEventsAmt |
| Oth Direct Expnss Other Events | $4,450,290 | OthDirectExpnssOtherEventsAmt |
| Gross Receipts Total | $30,857,948 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $29,733,448 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $1,124,500 | GrossRevenueTotalEventsAmt |
| Rent Fclty Costs Total Events | $1,626,413 | RentFcltyCostsTotalEventsAmt |
| Food And Beverage Total Events | $1,627,293 | FoodAndBeverageTotalEventsAmt |
| Entertainment Total Events | $2,988,329 | EntertainmentTotalEventsAmt |
| Oth Direct Expnss Total Events | $10,062,635 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $16,304,670 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | -$15,180,170 | NetIncomeSummaryAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2B, COLUMN (V): | FormAndLineReferenceDesc |
| Explanation | THE FOUNDATION FOR AIDS RESEARCH ACTUALLY PAID OUT $437,122 N FUNDRAISING EXPENSES FOR THE YEAR ENDING SEPTEMBER 30, 2025. THIS AMOUNT IS REPORTED ON PART IX, LINE 11(E). FOR PURPOSES OF SCHEDULE G, THE FOUNDATION IS REPORTING ALL AMOUNTS PAID TO THE CONSULTANTS LISTED ON PART I, REGARDLESS OF WHETHER SUCH AMOUNTS WERE PURE FUNDRAISING EXPENSES OR EVENT PRODUCTION COSTS. ON SCHEDULE G, THE TOTAL AMOUNT PAID TO THE ORGANIZATIONS LISTED IS $607,122 OF THAT $607,122 ONLY $437,122 WAS PAID FOR FUNDRAISING SERVICES, THE REMAINING $170,000 WAS PAID FOR EVENT PRODUCTION SERVICES. IN THE INTERESTS OF CLARITY, THE FOUNDATION WOULD ALSO LIKE TO MAKE CLEAR THAT THE COMPENSATION REPORTED AS HAVING BEEN PAID TO THE PROFESSIONAL FUNDRAISERS REPORTED ON SCHEDULE G IS REPORTED ON A FISCAL YEAR BASIS. SOME OF THOSE SAME FUNDRAISERS ARE REPORTED ON THE FOUNDATION'S TOP 5 HIGHEST PAID INDEPENDENT CONTRACTORS LIST (IN PART VII). IN COMPLIANCE WITH THE INSTRUCTIONS TO THE FORM 990, COMPENSATION REPORTED FOR PART VII IS REPORTED ON A CALENDAR YEAR BASIS. ACCORDINGLY, AMOUNTS ON PART VII AND SCHEDULE G WILL NOT RECONCILE. | ExplanationTxt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (18 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Non Cash AssistanceNonCashAssistanceAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|---|
| BOSTON CHILDREN'S HOSPITAL | |||||||||
| 3 BLACKFAN CIRCLE ROOM 3082 | BOSTON | MA | 10480 | 042774441 | 501(C)(3) | $10,204 | $0 | RESEARCH | |
| BROAD INSTITUTE OF MIT AND HARVARD | |||||||||
| 7 CAMBRIDGE CENTER SUITE 5011 | CAMBRIDGE | MA | 10250 | 263428781 | 501(C)(3) | $22,500 | $0 | RESEARCH | |
| CASE WESTERN RESERVE UNIVERSITY | |||||||||
| 0900 EUCLID AVENUE LC 4930 | CLEVELAND | OH | 10480 | 341018992 | 501(C)(3) | $410,149 | $0 | RESEARCH | |
| COLUMBIA UNIVERSITY | |||||||||
| 630 WEST 168TH ST BOX 49 | NEW YORK | NY | 21480 | 135598093 | 501(C)(3) | $56,133 | $0 | TREAT ASIA | |
| COMPASS INC | |||||||||
| 201 NORTH DIXIE HIGHWAY | LAKE WORTH | FL | 10150 | 650052657 | 501(C)(3) | $25,000 | $0 | RESEARCH | |
| FENWAY COMMUNITY HEALTH CENTER INC | |||||||||
| 1340 BOYLSTON STREET | BOSTON | MA | 10150 | 042510564 | 501(C)(3) | $50,000 | $0 | RESEARCH | |
| FRED HUTCHINSON CANCER CENTER | |||||||||
| 1100 FAIRVIEW AVE N | SEATTLE | WA | 10480 | 946036493 | 501(C)(3) | $319,175 | $0 | RESEARCH | |
| GLADSTONE INSTITUTES | |||||||||
| 1650 OWENS STREET | SAN FRANCISCO | CA | 10250 | 237203666 | 501(C)(3) | $22,500 | $0 | RESEARCH | |
| JOHNS HOPKINS UNIVERSITY | |||||||||
| 733 N BROADWAY MRB SUITE 117 | BALTIMORE | MD | 21350 | 520595110 | 501(C)(3) | $189,725 | $0 | TREAT ASIA | |
| NORTHWESTERN UNIVERSITY | |||||||||
| 633 CLARK STREET | EVANSTON | IL | 10250 | 362167817 | 501(C)(3) | $50,000 | $0 | RESEARCH | |
| OREGON HEALTH AND SCIENCE UNIVERSITY | |||||||||
| 3181 SW SAM JACKSON PARK ROAD | PORTLAND | OR | 10480 | 931176109 | 501(C)(3) | $32,078 | $0 | RESEARCH | |
| PREP4ALL INC | |||||||||
| 368 9TH AVE | NEW YORK | NY | 30000 | 853596607 | 501(C)(3) | $30,000 | $0 | PUBLIC POLICY | |
| THE WISAR INSTITUTE | |||||||||
| 3601 SPRUCE STREET | PHILADELPHIA | PA | 10480 | 236434390 | 501(C)(3) | $189,931 | $0 | RESEARCH | |
| UNIVERSITY OF CALIFORNIA SAN DIEGO | |||||||||
| 9500 GILMAN DRIVE | SAN DIEGO | CA | 10250 | 956006144 | 501(C)(3) | $22,500 | $0 | RESEARCH | |
| UNIVERSITY OF CALIFORNIA SAN FRANCISCO | |||||||||
| 3333 CALIFORNIA STREET SUITE 315 | SAN FRANCISCO | CA | 10350 | 946036493 | 501(C)(3) | $323,919 | $0 | RESEARCH | |
| UNIVERSITY OF MIAMI | |||||||||
| 1320 S DIXIE HIGHWAY SUITE 650 | CORAL GABLES | FL | 10480 | 590624458 | 501(C)(3) | $322,246 | $0 | RESEARCH | |
| UNIVERSITY OF MINNESOTA | |||||||||
| 200 OAK STREET SE | MINNEAPOLIS | MN | 10480 | 416007513 | 501(C)(3) | $344,570 | $0 | RESEARCH | |
| UNIVERSITY OF UTAH | |||||||||
| 15 NORTH MEDICAL DRIVE EAST JMRB | SALT LAKE CITY | UT | 10480 | 876000525 | 501(C)(3) | $37,604 | $0 | RESEARCH | 2100 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 18 | Total501c3OrgCnt |
| Total Other Org | 0 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | AMFAR PROVIDES GRANTS AND FELLOWSHIPS TO INDEPENDENT NOT-FOR-PROFIT ORGANIZATIONS THROUGH A PEER-REVIEW PROCESS. GRANT APPLICATIONS ARE FIRST REVIEWED BY THE FOUNDATION'S VOLUNTEER SCIENTIFIC ADVISORY COMMITTEE, WHICH COMPRISES RECOGNIZED EXPERTS IN THE MEDICAL, SCIENTIFIC, AND SOCIAL SCIENCES DISCIPLINES RELEVANT TO HIV AND AIDS. THE SCIENTIFIC ADVISORY COMMITTEE THEN SENDS ITS EVALUATIONS TO ONE OF THE THREE COMMITTEES (RESEARCH, GLOBAL INITIATIVES OR PUBLIC POLICY) OF THE FOUNDATION'S PROGRAM BOARD, WHICH SERVES IN AN ADVISORY CAPACITY TO THE BOARD OF TRUSTEES. AFTER A PROGRAM COMMITTEE HAS COMPLETED ITS REVIEW OF THE APPLICATIONS, IT PRESENTS ITS FUNDING RECOMMENDATIONS TO AMFAR'S EXECUTIVE COMMITTEE AND/OR THE FULL BOARD OF TRUSTEES FOR FINAL APPROVAL AND FUNDING AUTHORIZATION. GRANTS AND FELLOWSHIPS ARE PAYABLE OVER A ONE-TO-THREE YEAR PERIOD, AND ARE REVOCABLE AT AMFAR'S OPTION IF THE RECIPIENT'S PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE TERMS OF THE GRANT AND FELLOWSHIP AWARDS MAY BE LESS THAN THE ORIGINAL AWARD IF THE RECIPIENT DOES NOT USE THE FULL AMOUNT AWARDED. THEREFORE, A RESERVE FOR UNEXPENDED GRANTS AND FELLOWSHIPS HAS BEEN RECORDED. SUBAWARDS ARE GRANTS AWARDED TO NOT-FOR-PROFIT ORGANIZATIONS TO SUPPORT THE COSTS OF COLLABORATION AND PARTICIPATION IN HIV/AIDS-RELATED RESEARCH PROJECTS FOR WHICH AMFAR HAS SECURED RESTRICTED FUNDS. SUBAWARDS ARE PAYABLE OVER A ONE-YEAR PERIOD, ALTHOUGH ADVANCE PAYMENTS, IN FULL OR IN PART, MAY BE ISSUED FOLLOWING EXECUTION OF THE SUBAWARD AGREEMENT. SUBAWARDS ARE CONTINGENT UPON THE AVAILABILITY OF FUNDS AND ARE REVOCABLE IF THE RECIPIENTS' PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH SUBAWARD TERMS. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | Yes (1) | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (1) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (13 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KEVIN FROST | ||||||||||||||
| CHIEF EXECUTIVE OFFICER | $482,360 | $0 | $25,000 | $0 | $36,323 | $0 | $47,150 | $0 | $86,734 | $0 | $677,567 | $0 | $208 | $0 |
| BRADLEY JENSEN ASSISTANT | ||||||||||||||
| TREASURER/CFO, THRU JULY 2025 | $376,610 | $0 | $0 | $0 | $0 | $0 | $24,150 | $0 | $67,046 | $0 | $467,806 | $0 | $0 | $0 |
| GREGORIO MILLET | ||||||||||||||
| VICE PRESIDENT, PUBLIC POLICY | $325,758 | $0 | $0 | $0 | $0 | $0 | $23,274 | $0 | $67,046 | $0 | $416,078 | $0 | $0 | $0 |
| KYLE CLIFFORD | ||||||||||||||
| VICE PRESIDENT OF DEVELOPMENT | $292,133 | $0 | $0 | $0 | $0 | $0 | $21,076 | $0 | $67,046 | $0 | $380,255 | $0 | $0 | $0 |
| ANNETTE SOHN | ||||||||||||||
| VICE PRESIDENT, TREAT ASIA | $282,080 | $0 | $0 | $0 | $0 | $0 | $19,750 | $0 | $10,615 | $0 | $312,445 | $0 | $0 | $0 |
| SEBASTIAN GHEITH | ||||||||||||||
| GENERAL COUNSEL, ASST SECRETARY | $201,976 | $0 | $0 | $0 | $0 | $0 | $14,763 | $0 | $86,734 | $0 | $303,473 | $0 | $0 | $0 |
| ANTHONY ANCONA | ||||||||||||||
| VICE PRESIDENT OF HUMAN RESOURCES | $211,292 | $0 | $0 | $0 | $0 | $0 | $15,353 | $0 | $67,046 | $0 | $293,691 | $0 | $0 | $0 |
| ANDREW MCINNES | ||||||||||||||
| DIRECTOR, PUBLICATIONS | $197,892 | $0 | $0 | $0 | $0 | $0 | $14,133 | $0 | $67,046 | $0 | $279,071 | $0 | $0 | $0 |
| CHRISTOPHER FREDERICK | ||||||||||||||
| SPECIAL EVENTS DIRECTOR | $196,451 | $0 | $0 | $0 | $0 | $0 | $14,083 | $0 | $54,279 | $0 | $264,813 | $0 | $0 | $0 |
| BENNAH SERFATY | ||||||||||||||
| SENIOR DIRECTOR OF COMMUNICATIONS | $153,102 | $0 | $0 | $0 | $0 | $0 | $11,250 | $0 | $86,734 | $0 | $251,086 | $0 | $0 | $0 |
| RONALD KIRK ASSISTANT TREASURER | ||||||||||||||
| CONTROLLER, THRU JUNE 2025 | $191,077 | $0 | $0 | $0 | $0 | $0 | $13,642 | $0 | $28,160 | $0 | $232,879 | $0 | $0 | $0 |
| EMMA KOSTURA | ||||||||||||||
| DIRECTOR, PHILANTHROPY | $142,196 | $0 | $0 | $0 | $0 | $0 | $4,159 | $0 | $72,498 | $0 | $218,853 | $0 | $0 | $0 |
| JAMES SHAKLEFORD FORMER | ||||||||||||||
| VP OF PUBLIC INFORMATION | $163,552 | $0 | $0 | $0 | $0 | $0 | $11,211 | $0 | $18,488 | $0 | $193,251 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 4B | CHIEF EXECUTIVE OFFICER, KEVIN FROST, PARTICIPATED IN A SUPPLEMENTAL NON-QUALIFIED RETIREMENT PLAN. IN CALENDAR YEAR 2024, AMFAR CONTRIBUTED $36,323 INTO MR. FROST'S NON-QUALIFIED RETIREMENT PLAN. THIS AMOUNT IS NOT REPORTED IN SCHEDULE J, PART II, COLUMN (C) BECAUSE THE CONTRIBUTION AMOUNT WAS DISTRIBUTED TO MR. FROST WITHIN THE SAME CALENDAR YEAR. INCLUDED IN SCHEDULE J, COLUMN (B) (III) IS MR. FROST'S 2024 EMPLOYER-FUNDED 457(F) CONTRIBUTION OF $36,323. |
| PART I, LINE 7 | THE ORGANIZATION PAID BOARD APPROVED DISCRETIONARY BONUSES TO CERTAIN INDIVIDUALS LISTED IN PART II AS REPORTED IN COLUMN B(II) FOR THE APPLICABLE INDIVIDUALS. |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 8 | ContributionCnt |
| Noncash Contributions Rpt F990 | $217,568 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | AVG. SELLING PRICE | MethodOfDeterminingRevenuesTxt |
Food Inventory FoodInventoryGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 8 | ContributionCnt |
| Noncash Contributions Rpt F990 | $205,968 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | COST | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form8283 Received | 0 | Form8283ReceivedCnt |
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | 0 | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, COLUMN (B): | FormAndLineReferenceDesc |
| Explanation | THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS IN PART I, COLUMN (B) OF SCHEDULE M. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (10 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 1: | THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: AMERICAN FOUNDATION FOR AIDS RESEARCH AMFAR AIDS RESEARCH FOUNDATION AMFAR IS DEDICATED TO ADVANCING SCIENTIFIC DISCOVERY TO IMPROVE GLOBAL HEALTH, WITH A PRIMARY AND ENDURING COMMITMENT TO ENDING THE HIV/AIDS EPIDEMIC. THE FOUNDATION ACCOMPLISHES THIS MISSION THROUGH: RESEARCH TO EXPLORE INNOVATIVE SCIENTIFIC APPROACHES FOR PREVENTING, TREATING, AND CURING HIV AND OTHER INFECTIOUS DISEASE THREATS AND ENHANCING THE HEALTH AND SURVIVAL OF PEOPLE LIVING WITH HIV; INTERNATIONAL INITIATIVES TO FACILITATE THE DEVELOPMENT AND IMPLEMENTATION OF EFFECTIVE RESEARCH, TREATMENT, PREVENTION, AND EDUCATION STRATEGIES IN LOW- AND MIDDLE-INCOME COUNTRIES; PUBLIC POLICY ANALYSIS AND THE ADVOCACY OF RATIONAL AND COMPASSIONATE POLICIES THAT PROMOTE PUBLIC HEALTH AND PROTECT THE RIGHTS OF PEOPLE THREATENED BY HIV/AIDS; AND PUBLIC INFORMATION PROGRAMS TO BUILD AWARENESS OF THE CONTINUED THREAT HIV/AIDS POSES AND TO PROVIDE UP-TO-DATE MEDICAL, SCIENTIFIC, AND PREVENTION INFORMATION TO PEOPLE LIVING WITH HIV/AIDS, HEALTHCARE PROFESSIONALS, AND THE PUBLIC. |
| FORM 990, PART III, LINE 4A | SUPPORTING CUTTING-EDGE RESEARCH AMFAR AWARDS TWO MAIN TYPES OF GRANTS: HORIZON (FORMERLY, ARCHE) GRANTS, WHICH SUPPORT COLLABORATIVE, CROSS-DISCIPLINE RESEARCH INITIATIVES AIMED AT CURING HIV OR ADDRESSING OTHER HEALTH CHALLENGES RELATED TO VIROLOGY AND IMMUNOLOGY; AND TARGET GRANTS, WHICH SUPPORT STUDIES AIMED AT UNCOVERING VITAL KNOWLEDGE DIRECTLY APPLICABLE TO CLINICAL OR PRE-CLINICAL CURE EFFORTS. THROUGH ITS MATHILDE KRIM FELLOWSHIPS IN BIOMEDICAL RESEARCH, AMFAR PROVIDES CRITICAL SUPPORT TO OUTSTANDING YOUNG SCIENTISTS WHO REPRESENT THE FUTURE OF HIV RESEARCH. TARGET GRANTS THREE SCIENTISTS RECEIVED TARGET GRANTS IN SUPPORT OF THEIR INNOVATIVE PROJECTS. LEARNING FROM STEM CELL CURES STEM CELL TRANSPLANTATION USING DONOR CELLS MISSING CCR5, A CO-RECEPTOR NEEDED FOR HIV INFECTION HAS CURED EIGHT INDIVIDUALS, AND SEEMINGLY A NINTH. TWO OTHER INDIVIDUALS WHO RECEIVED STEM CELL TRANSPLANTS USING WILDTYPE, OR NON-MUTATED, CELLS HAVE ALSO BEEN CURED. WHILE STEM CELL TRANSPLANTS ARE TOO HIGH-RISK TO WORK FOR EVERYONE WHO NEEDS A CURE, THE RESEARCH HAS PROVIDED NEW INSIGHTS ABOUT ERADICATING HIV OR CONTROLLING THE VIRUS LONG-TERM WITHOUT ART. TWO AMFAR GRANTEES ARE BUILDING ON THESE INSIGHTS TO DEVELOP STRATEGIES THAT ARE SCALABLE, ACCESSIBLE, AND AFFORDABLE FOR THE OVER 40 MILLION PEOPLE LIVING WITH HIV. THE CURRENT "HOLY GRAIL" OF HIV CURE RESEARCH IS ADMINISTERING A SINGLE INJECTION OF A GENE-EDITING ENZYME SUCH AS CRISPR-CAS TO INACTIVATE THE CCR5 GENE IN PEOPLE WITH HIV, EFFECTING A CURE WITHOUT THE NEED FOR A STEM CELL TRANSPLANT. ELENA HERRERA-CARRILLO, PHD, OF THE UNIVERSITY OF AMSTERDAM IN THE NETHERLANDS, RECEIVED FUNDING FROM AMFAR TO USE LIPID NANOPARTICLES (LNPS) TO DELIVER GENE-EDITING ENZYMES CAPABLE OF INACTIVATING THE CCR5 GENE, AND THUS RENDERING THOSE CELLS IMMUNE TO HIV, AS WELL AS CUTTING OUT HIV FROM CELLS ALREADY INFECTED. BLOOD SAMPLES FROM PEOPLE WITH HIV WILL BE OBTAINED THROUGH A COLLABORATION IN UGANDA. IN ADDITION, SHE WILL BE TRAINING UGANDAN SCIENTISTS IN HER LAB IN AMSTERDAM TO REPRODUCE THIS TECHNIQUE AND, IF IT SHOWS PROMISE, TRANSFER THAT KNOWLEDGE AND RELATED MANUFACTURING PROCESSES TO AFRICA (EASTERN AND SOUTHERN AFRICA ACCOUNTS FOR OVER HALF OF ALL PEOPLE LIVING WITH HIV). JONAH SACHA, PHD, OF OREGON HEALTH AND SCIENCE UNIVERSITY IN PORTLAND, ALSO AIMS TO REPRODUCE THE CURATIVE EFFECTS OF STEM CELL TRANSPLANTATION WITHOUT RESORTING TO THE COSTLY, HIGH-RISK PROCEDURE. IN A 2023 STUDY SUPPORTED BY AMFAR, DR. SACHA REPORTED THAT A MONKEY INFECTED WITH SIV, THE SIMIAN COUNTERPART OF HIV, HAD SEEMINGLY BEEN CURED AFTER UNDERGOING A STEM CELL TRANSPLANT. CRUCIALLY, THE TRANSPLANT INVOLVED "NORMAL" DONOR CELLS AS OPPOSED TO CELLS WITH MUTATED, INACTIVE CCR5. HE PROPOSED THAT ALLOGENEIC IMMUNITY, OR A GRAFT-VERSUS-HOST RESPONSEA KEY PART OF CERTAIN CANCER CURES FOLLOWING STEM CELL TRANSPLANTS WITH NORMAL DONORSWAS INVOLVED AND MIGHT BE REPLICATED WITHOUT REQUIRING A TRANSPLANT. WITH A 2025 AMFAR GRANT, DR. SACHA IS BUILDING ON PRELIMINARY DATA THAT A "MINOR" ANTIGEN ON WHITE BLOOD CELLS IS INVOLVED AND ADMINISTER KILLER CD8+ T CELLS TRAINED ON THIS TARGET TO SIV-INFECTED MONKEYS TO SEE IF THIS APPROACH WILL REPRODUCE THE EFFECTS OF THE TRANSPLANT ITSELF, OPENING THE WAY FOR SIMILAR APPROACHES IN HUMANS. WAKING UP THE HIV RESERVOIR MUCH OF THE HIV RESERVOIR, THE PRIMARY BARRIER TO A CURE, PERSISTS IN DORMANCY, BEYOND THE REACH OF ANTIRETROVIRAL THERAPY (ART) AND UNRECOGNIZED BY THE IMMUNE SYSTEM. ONE APPROACH TO TARGETING THESE UNINFECTED CELLS IS TO WAKE THEM UP AND MAKE THEM VISIBLE AND THUS EASIER TARGETS. ONE WAKEUP METHOD INVOLVES LATENCY-REVERSING AGENTS (LRAS)CHEMICALS CAPABLE OF ACTIVATING HIV AT THE LEVEL OF GENE TRANSCRIPTION. WITH HIS GRANT, ALEXANDER PASTERNAK, PHD, OF THE ACADEMIC MEDICAL CENTER OF THE UNIVERSITY OF AMSTERDAM, IS INVESTIGATING A DIFFERENT LATENCY-REVERSAL STRATEGY. DR. PASTERNAK AND HIS TEAM ARE TESTING HIS THEORY THAT CURRENT LRAS ARE ACTING ON INSUFFICIENT TARGETS AND ARE THUS INCAPABLE OF STIMULATING HIV AT POINTS OTHER THAN TRANSCRIPTION. WORKING WITH T CELLS FROM PEOPLE WITH HIV TAKING ART, HE WILL ATTEMPT TO IDENTIFY NOVEL COMBINATIONS OF LRAS THAT CAN REMOVE ALL OBSTACLES TO FULL RESERVOIR ACTIVATION. MATHILDE KRIM FELLOWSHIPS IN BIOMEDICAL RESEARCH IN 2025, FOUR HIV RESEARCHERS WERE AWARDED FELLOWSHIPS. A PAST FELLOW RECEIVED A PHASE II EXTENSION AWARD. INSTEAD OF TARGETING THE HIV RESERVOIR BY REACTIVATING INFECTED CELLS IN ORDER TO ELIMINATE THEM, A STUDY BY FRANCISCO ZAPATERO BELINCHON, PHD, OF THE GLADSTONE INSTITUTES IN SAN FRANCISCO, IS USING A "BLOCK AND LOCK" APPROACH, AIMING TO LOCK HIV INTO A SILENT STATE INDEFINITELY, PREVENTING IT FROM EVER REACTIVATING. HE WILL USE A POWERFUL NEW TOOL CALLED "BRECOFF" THAT COMBINES A PROTEIN CALLED BREC1 THAT FINDS THE PART OF THE GENOME WHERE HIV HIDES WITH "MOLECULAR SILENCERS" THAT SHUT DOWN HIV ACTIVITY BY MODIFYING HOW DNA IS PACKAGED. TIANLING OU, PHD, OF MIT AND HARVARD'S BROAD INSTITUTE, PROPOSES A BRAND-NEW AND EXTREMELY PROMISING STRATEGY TO GUIDE THE IMMUNE SYSTEM TO MOUNT A POWERFUL RESPONSE TO HIV FROM THE OUTSET. DR. OU WILL USE A SPECIALIZED MOUSE MODEL TO TEST WHETHER HIV-FIGHTING ANTIBODIES PRODUCED EARLY IN THE COURSE OF INFECTION CAN BE NUDGED INTO BECOMING MUCH MORE POTENT BROADLY NEUTRALIZING ANTIBODIES (BNABS) THROUGH A SERIES OF CAREFULLY TIMED INTERVENTIONS. IF SUCCESSFUL, THE STUDY COULD PROVIDE A PATHWAY TO DEVELOPING PROTECTION AGAINST HIV USING ITS OWN IMMUNE MACHINERY. HANNAH KING, PHD, OF THE PETER DOHERTY INSTITUTE IN MELBOURNE, AUSTRALIA, AIMS TO HARNESS THE POWER OF CHECKPOINT INHIBITORS, USED SUCCESSFULLY IN CANCER TREATMENT, TO REINVIGORATE EXHAUSTED HIV-FIGHTING T CELLS. USING CUTTING-EDGE SINGLE-CELL ANALYSIS, DR. KING WILL IDENTIFY PATTERNS AMONG SAMPLES FROM PREVIOUS CLINICAL TRIALS TO PREDICT WHO WILL RESPOND BEST TO THIS TREATMENT. THE GOAL IS TO FIND IMMUNE MARKERS OR GENE SIGNATURES THAT ACT LIKE FINGERPRINTS FOR A SUCCESSFUL RESPONSE. THESE INSIGHTS COULD MAKE CHECKPOINT THERAPY SAFER AND MORE EFFECTIVE FOR PEOPLE WITH HIV AND HELP REFINE FUTURE CURE STRATEGIES. A STUDY BY ELIZABETH HASTIE, MD, OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO, COULD INTEGRATE GENDER-AFFIRMING CARE INTO HIV CURE RESEARCH, ADDRESSING AN URGENT GAP IN KNOWLEDGE FOR A COMMUNITY HEAVILY IMPACTED BY HIV: TRANSGENDER WOMEN. DR. HASTIE WILL EXAMINE THE IMPACT OF HORMONE THERAPY, SPECIFICALLY ESTROGEN, ON THE IMMUNE SYSTEM OF TRANSGENDER WOMEN LIVING WITH HIV. STUDIES SUGGEST ESTROGEN MAY INFLUENCE HOW CERTAIN IMMUNE CELLS RESPOND TO THE VIRUS, POTENTIALLY HELPING CONTROL IT MORE EFFECTIVELY. DR. HASTIE HOPES TO UNDERSTAND WHETHER HORMONE THERAPY CAN ENHANCE ANTIVIRAL IMMUNITY OR EVEN RESHAPE HIV'S ABILITY TO PERSIST IN THE BODY. STEVEN DE TAEYE, PHD, OF THE UNIVERSITY OF AMSTERDAM, RECEIVED A PHASE II KRIM AWARD TO CONTINUE HIS WORK ON ANTIBODY CONJUGATES, WHICH BIND INTERVENTIONS TO ANTIBODIES AS A MEANS OF DELIVERING THEM TO SPECIFIC CELLS IN ORDER TO TARGET HIV. A CURE RESEARCH MILESTONE A RECENT STUDY, SUPPORTED BY AN AMFAR TARGET GRANT, TESTED A NOVEL WAY TO REACTIVATE LATENT VIRUS WHILE LEAVING UNINFECTED CELLS UNTOUCHED ACHIEVED A BREAKTHROUGH. LED BY PROF. SHARON LEWIN, A TEAM OF RESEARCHERS AT THE DOHERTY INSTITUTE IN MELBOURNE, AUSTRALIA, INTRODUCED SPECIALIZED LIPID NANOPARTICLES (LNP X), OR "FAT BUBBLES," CAPABLE OF INSERTING MRNA, A PIECE OF GENETIC MATERIAL, DIRECTLY INTO CD4+ T CELLS WITHOUT HARMING UNINFECTED CELLS. IN THEIR LNP X, PROF. SHARON LEWIN'S GROUP ENCAPSULATED MRNA ENCODING A VIRAL PROTEIN CALLED TAT, WHICH ACTS LIKE A MOLECULAR ALARM CLOCK. ONCE INSIDE THE CELL, IT WAKES UP THE DORMANT VIRUS, MAKING THE INFECTED CELL VISIBLE TO THE IMMUNE SYSTEM, WHICH CAN THEN ELIMINATE IT. TAT DELIVERED VIA LNP X REACTIVATED LATENT HIV IN CD4+ T CELLS FROM PEOPLE LIVING WITH HIV ON ART, OUTPERFORMING CONVENTIONAL LATENCY-REVERSAL STRATEGIES AND WITHOUT TRIGGERING IMMUNE ACTIVATION AND BROAD TOXICITY. THE TEAM ALSO USED LNP X TO DELIVER A CRISPR-BASED GENE ACTIVATOR, WHICH COULD POTENTIALLY BE DIRECTED TO PUSH THE VIRUS OUT OF HIDING WITH GREAT SPECIFICITY. THE RESEARCHERS ARE FOCUSING ON NOW IS MAKING SURE THAT THE REACTIVATED CELLS ARE PROPERLY TARGETED AND ELIMINATED BY THE IMMUNE SYSTEM. SHARING KNOWLEDGE IN 2025 AMFAR-FUNDED RESEARCHERS PUBLISHED 27 RESEARCH PAPERS (25 ON HIV; TWO ON COVID-19) IN LEADING PEER-REVIEWED JOURNALS, INCLUDING JCI INSIGHT, NATURE COMMUNICATIONS, AND JOURNAL OF VIROLOGY. |
| FORM 990, PART III, LINE 4A | AMFAR-SUPPORTED RESEARCHERS ALSO PARTICIPATED IN PROMINENT CONFERENCES. AT THE INTERNATIONAL AIDS SOCIETY CONFERENCE ON HIV SCIENCE IN KIGALI, RWANDA, IN JULY 2025, EIGHT SCIENTISTS PRESENTED ON INNOVATIVE STRATEGIES TO END AIDS. PROF. SHARON LEWIN AND DR. OLE SGAARD FACILITATED SESSIONS ON THE IMPACT OF CO-INFECTIONS AND VIRAL AND HOST DIVERSITY ON HIV CURES. ALSO FOCUSED ON HIV CURE STRATEGIES, DRS. MATTHIAS LICHTERFELD, MELANIE OTT, AND LISHOMWA NDHLOVU DISCUSSED SILENCING THE HIV RESERVOIR. IN ADDITION, AMFAR GRANTEE DR. XU G. YU OF THE RAGON INSTITUTE OF MGH, MIT AND HARVARD GAVE A PLENARY ON THE HIV RESERVOIR AND NOVEL APPROACHES TO MEASURING AND TESTING HIV CURE STRATEGIES. SHE ALSO COAUTHORED A STUDY IN FY2025 THAT EXAMINED THE IMPACT OF LONG-TERM ANTIRETROVIRAL THERAPY STARTED DURING INFANCY TO LEARN MORE ABOUT THE POWER OF THE PEDIATRIC IMMUNE SYSTEM. AMONG THE 11 STUDIES BY AMFAR GRANTEES PRESENTED AT THE CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI), ONE STUDY, FUNDED BY AMFAR, THE NIH, AND THE BILL AND MELINDA GATES FOUNDATION, BUILT UPON A GROUNDBREAKING UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (UCSF)-AMFAR HIV CURE TRIAL THAT ESTABLISHED PROOF OF CONCEPT THAT A COMBINATION OF IMMUNOTHERAPY AGENTS COULD INDUCE POST-TREATMENT CONTROL OF HIV. FOR THE NEW STUDY, RESEARCHERS LED BY DR. MICHAL PELUSO, OF UCSF, EXAMINED THE EARLY VIRAL DYNAMICS WITHIN INDIVIDUALS WHOSE TREATMENT HAD BEEN PAUSED, A LIKELY PREDICTOR OF HOW WELL THE IMMUNE SYSTEM CAN CONTROL HIV. THE FINDINGS SUGGEST THAT INDIVIDUALS WHO ARE DESTINED TO CONTROL HIVSPONTANEOUSLY OR AFTER A CURE INTERVENTIONEXHIBIT EVIDENCE OF POST-TREATMENT CONTROL IMMEDIATELY AFTER TREATMENT IS PAUSED. THUS, THE RESEARCHERS SUGGEST THAT FUTURE CLINICAL TRIALS NEED TO TARGET THE EARLIEST TIMEPOINTS OF HIV AND IMMUNE SYSTEM INTERACTION, WHEN THEY FIRST ENCOUNTER ONE ANOTHER. |
| FORM 990, PART III, LINE 4D | THROUGHOUT THE YEAR, AMFAR STAFF PUBLISHED ARTICLES ON A RANGE OF TOPICS IN ACADEMIC AND POLICY JOURNALS, INCLUDING: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, NOVEMBER 2024, "THE GROUND HAS SHIFTED UNDER PEPFAR: WHAT DOES THAT MEAN FOR ITS FUTURE?" AIDS PATIENT CARE & STDS, DECEMBER 2024, "REJECTION OF FEDERAL GUIDANCE BY SOUTHERN US STATES AND PROJECTED CONSEQUENCES FOR ENDING THE HIV EPIDEMIC" JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, FEBRUARY 2025, "EARLY IMPACTS OF THE PEPFAR STOP-WORK ORDER: A RAPID ASSESSMENT" THE LANCET, FEBRUARY 2025, "PEPFAR UNDER REVIEW: WHAT'S AT STAKE FOR PEPFAR'S FUTURE" THE LANCET, MAY 2025, "PROTECTING AFRICA'S CHILDREN FROM EXTREME RISK: A RUNWAY OF SUSTAINABILITY FOR PEPFAR PROGRAMMES" JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, SEPTEMBER 2025, EXCESS HIV INFECTIONS AND COSTS ASSOCIATED WITH REDUCTIONS IN HIV PREVENTION SERVICES IN THE US" JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, SEPTEMBER 2025, "IMPACT OF THE ANTI-HOMOSEXUALITY ACT ON HIV SERVICE DELIVERY IN UGANDA: EVIDENCE FROM COMMUNITY-LED MONITORING" POLICY STAFF ALSO CONTRIBUTED INSIGHTS TO MAJOR NEWS OUTLETS SUCH AS THE NEW YORK TIMES, NPR, WASHINGTON POST, PROPUBLICA, THE INDEPENDENT, AGENCE FRANCE PRESSE, AND POZ MAGAZINE, AMONG OTHERS. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FORM 990 WAS PREPARED BY A NATIONALLY RENOWNED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. A COPY OF THE FORM 990 WAS CIRCULATED TO THE FULL BOARD OF TRUSTEES FOR DISCUSSION AND COMMENT. EACH BOARD MEMBER WAS PROVIDED AMPLE OPPORTUNITY TO COMMENT ON THE INFORMATION CONTAINED IN THE 990 PRIOR TO ITS FILING WITH THE INTERNAL REVENUE SERVICE. |
| FORM 990, PART VI, SECTION B, LINE 12C | EACH OFFICER, DIRECTOR, TRUSTEE AND KEY EMPLOYEE OF AMFAR ("FOUNDATION") IS REQUIRED TO ANNUALLY DISCLOSE ANY CONFLICTS OF INTEREST THAT ARISE BY VIRTUE OF EMPLOYMENT, BOARD SERVICE, OR POSITION WITH THE FOUNDATION. THE FOUNDATION MONITORS COMPLIANCE WITH ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL QUESTIONNAIRE/DISCLOSURE STATEMENT THAT IS DISTRIBUTED TO THESE INDIVIDUALS. POTENTIAL CONFLICTS ARE INVESTIGATED IMMEDIATELY. |
| FORM 990, PART VI, SECTION B, LINE 15 | AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. AMFAR'S LAST INDEPENDENT COMPENSATION STUDY WAS CONDUCTED IN AUGUST OF 2020 TO ENSURE THAT THE PRESIDENT & CEO'S COMPENSATION IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED ANNUALLY BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. |
| FORM 990, PART VI, SECTION C, LINE 19 | AMFAR MAKES ITS FORM 990 AVAILABLE TO THE PUBLIC BY RETAINING A COPY AT ITS PLACE OF BUSINESS AND ON ITS WEBSITE, WWW.AMFAR.ORG. THE FORM 990 IS LIKEWISE PUBLISHED ON THE INTERNET AT WWW.GUIDESTAR.ORG. THE FOUNDATION'S FINANCIAL STATEMENTS ARE MADE AVAILABLE IN ITS ANNUAL REPORT AND ON ITS WEBSITE. THE FOUNDATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE NOT ORDINARILY MADE AVAILABLE TO THE PUBLIC, BUT, IF REQUESTED WILL BE PROVIDED AT MANAGEMENT'S DISCRETION. |
| FORM 990, PART XI, LINE 9: | OVERACCRUAL OF GRANT EXPENSE 33,832. WRITE OFF OF UNCOLLECTIBLE PLEDGES -403,708. |
| FORM 990, PART XII, LINE 2C: | THE ORGANIZATION HAS A COMMITTEE THAT IS RESPONSIBLE FOR THE OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT ACCOUNTANT. THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. |